Patent Grant
11857344
This invention relates generally to the field of analyte monitoring, such as continuous glucose monitoring.
Diabetes is a chronic disease in which the body does not produce or properly utilize insulin, a hormone that regulates blood glucose. Insulin may be administered to a diabetic patient to help regulate blood glucose levels, though blood glucose levels must nevertheless be carefully monitored to help ensure that timing and dosage are appropriate. Without proper management of their condition, diabetic patients may suffer from a variety of complications resulting from hyperglycemia (high blood sugar levels) or hypoglycemia (low blood sugar levels).
Blood glucose monitors help diabetic patients manage their condition by measuring blood glucose levels from a sample of blood. For example, a diabetic patient may obtain a blood sample through a fingerstick sampling mechanism, transfer the blood sample to a test strip with suitable reagent(s) that react with the blood sample, and use a blood glucose monitor to analyze the test strip to measure glucose level in that blood sample. However, a patient using this process can typically only measure his or her glucose levels at discrete instances in time, which may fail to capture a hyperglycemia or hypoglycemia condition in a timely manner. Yet a more recent variety of glucose monitor is a continuous glucose monitor (CGM) device, which includes implantable transdermal electrochemical sensors that are used to continuously detect and quantify blood glucose levels by proxy measurement of glucose levels in the subcutaneous interstitial fluid. However, conventional CGM devices also have weaknesses including tissue trauma from insertion and signal latency (e.g., due to the time required for the glucose analyte to diffuse from capillary sources to the sensor). These weaknesses also lead to a number of drawbacks, such as pain experienced by the patient when electrochemical sensors are inserted, and limited accuracy in glucose measurements, particularly when blood glucose levels are changing rapidly. Accordingly, there is a need for a new and improved analyte monitoring system.
In some variations, a microneedle array-based analyte monitoring device includes a working electrode, a reference electrode, a counter electrode, an analog front end, and a controller. The working electrodes includes an electrochemical sensing coating configured to generate a sensing current indicative of a redox reaction of an analyte at a surface of the working electrode, and the working electrode is positioned on a surface of a distal portion of a first microneedle in a microneedle array. The reference electrode is positioned on a surface of a distal portion of a second microneedle in the microneedle array. The counter electrode is positioned on a surface of a distal portion of a third microneedle in the microneedle array. The analog front end is configured to maintain a fixed potential relationship between the working electrode and the reference electrode and to allow potential of the counter electrode to swing to sustain the redox reaction at the working electrode. The controller is in communication with the analog front end and is configured to: monitor a counter electrode voltage at the counter electrode; identify a characteristic of the counter electrode voltage that meets or exceeds a threshold value; determine, in response to identifying the characteristic of the counter electrode voltage that exceeds the threshold value, a correlation between the counter electrode voltage and the sensing current; and apply, based on the characteristic of the counter electrode voltage and the correlation, a mode of operation to the microneedle array-based analyte monitoring device.
In some variations, a method includes monitoring a counter electrode voltage at a counter electrode of a microneedle array-based analyte monitoring device, the counter electrode positioned on a surface of a distal portion of a first microneedle in the microneedle array; identifying a characteristic of the counter electrode voltage that meets or exceeds a threshold value; determining, in response to identifying the characteristic of the counter electrode voltage that exceeds the threshold value, a correlation between the counter electrode voltage and a sensing current, the sensing current generated at a surface of a working electrode of the microneedle array-based analyte monitoring device; and applying, based on the characteristic of the counter electrode voltage and the correlation, a mode of operation to the microneedle array-based analyte monitoring device. The working electrode may include an electrochemical sensing coating configured to generate the sensing current indicative of a redox reaction of an analyte at the surface of the working electrode, the working electrode positioned on a surface of a distal portion of a second microneedle in a microneedle array. The microneedle array-based analyte monitoring device may further include a reference electrode positioned on a surface of a distal portion of a third microneedle in the microneedle array, and an analog front end configured to maintain a fixed potential relationship between the working electrode and the reference electrode and to allow potential of the counter electrode to swing to sustain the redox reaction at the working electrode.
In some variations, the characteristic of the counter electrode voltage include one or more of a rate of change of the counter electrode voltage or a lower compliance limit of the counter electrode voltage.
In some variations, changes in the counter electrode voltage and changes in the sensing current are indicative of the correlation between the counter electrode voltage and the sensing current.
In some variations, the mode of operation includes disregarding the sensing current if the changes in the counter electrode voltage correspond with the changes in the sensing current and if the rate of change of the counter electrode voltage exceeds a threshold rate of change.
In some variations, the controller is further configured to interrupt the mode of operation of disregarding the sensing current, in response to a subsequent determination that the rate of change of the counter electrode voltage does not exceed the threshold rate of change.
In some variations, the mode of operation includes discontinuing application of a potential between the working electrode and the reference electrode if the lower compliance limit of the counter electrode voltage meets a threshold compliance limit.
In some variations, the mode of operation includes discontinuing application of a potential between the working electrode and the reference electrode if the changes in the counter electrode voltage deviate from the changes in the sensing current and if the rate of change of the counter electrode voltage exceeds a threshold rate of change.
In some variations, the microneedle array-based analyte monitoring device further includes one or more additional working electrodes, each of the one or more additional working electrodes generating a respective sensing current. The controller is further configured to determine, in response to identifying the characteristic of the counter electrode voltage that exceeds the threshold value, a correlation between the counter electrode voltage and the respective sensing current.
In some variations, the mode of operation is further based on the correlation between the counter electrode voltage and the respective sensing current.
In some variations, the sensing current at the working electrode and the respective sensing current at the one or more additional working electrodes are combined to determine a combined correlation.
Non-limiting examples of various aspects and variations of the invention are described herein and illustrated in the accompanying drawings.
As generally described herein, an analyte monitoring system may include an analyte monitoring device that is worn by a user and includes one or more sensors for monitoring at least one analyte of a user. The sensors may, for example, include one or more electrodes configured to perform electrochemical detection of at least one analyte. The analyte monitoring device may communicate sensor data to an external computing device for storage, display, and/or analysis of sensor data. For example, as shown in
The analyte monitoring devices described herein have characteristics that improve a number of properties that are advantageous for a continuous analyte monitoring device such as a continuous glucose monitoring (CGM) device. For example, the analyte monitoring device described herein have improved sensitivity (amount of sensor signal produced per given concentration of target analyte), improved selectivity (rejection of endogenous and exogenous circulating compounds that can interfere with the detection of the target analyte), and improved stability to help minimize change in sensor response over time through storage and operation of the analyte monitoring device. Additionally, compared to conventional continuous analyte monitoring devices, the analyte monitoring devices described herein have a shorter warm-up time that enables the sensor(s) to quickly provide a stable sensor signal following implantation, as well as a short response time that enables the sensors(s) to quickly provide a stable sensor signal following a change in analyte concentration in the user. Furthermore, as described in further detail below, the analyte monitoring devices described herein may be applied to and function in a variety of wear sites, and provide for pain-free sensor insertion for the user. Other properties such as biocompatibility, sterilizability, and mechanical integrity are also optimized in the analyte monitoring devices described herein.
Although the analyte monitoring systems described herein may be described with reference to monitoring of glucose (e.g., in users with Type 2 diabetes, Type 1 diabetes), it should be understood that such systems may additionally or alternatively be configured to sense and monitor other suitable analytes. As described in further detail below, suitable target analytes for detection may, for example, include glucose, ketones, lactate, and cortisol. One target analyte may be monitored, or multiple target analytes may be simultaneously monitored (e.g., in the same analyte monitoring device). For example, monitoring of other target analytes may enable the monitoring of other indications such as stress (e.g., through detection of rising cortisol and glucose) and ketoacidosis (e.g., through detection of rising ketones).
As shown in
An electronics system 120 may be at least partially arranged in the housing 112 and include various electronic components, such as sensor circuitry 124 configured to perform signal processing (e.g., biasing and readout of electrochemical sensors, converting the analog signals from the electrochemical sensors to digital signals, etc.). The electronics system 120 may also include at least one microcontroller 122 for controlling the analyte monitoring device 110, at least one communication module 126, at least one power source 130, and/or other various suitable passive circuitry 127. The microcontroller 122 may, for example, be configured to interpret digital signals output from the sensor circuitry 124 (e.g., by executing a programmed routine in firmware), perform various suitable algorithms or mathematical transformations (e.g., calibration, etc.), and/or route processed data to and/or from the communication module 126. In some variations, the communication module 126 may include a suitable wireless transceiver (e.g., Bluetooth transceiver or the like) for communicating data with an external computing device 102 via one or more antennas 128. For example, the communication module 126 may be configured to provide uni-directional and/or bi-directional communication of data with an external computing device 102 that is paired with the analyte monitoring device 110. The power source 130 may provide power for the analyte monitoring device 110, such as for the electronics system. The power source 130 may include battery or other suitable source, and may, in some variations, be rechargeable and/or replaceable. Passive circuitry 127 may include various non-powered electrical circuitry (e.g., resistors, capacitors, inductors, etc.) providing interconnections between other electronic components, etc. The passive circuitry 127 may be configured to perform noise reduction, biasing and/or other purposes, for example. In some variations, the electronic components in the electronics system 120 may be arranged on one or more printed circuit boards (PCB), which may be rigid, semi-rigid, or flexible, for example. Additional details of the electronics system 120 are described further below.
In some variations, the analyte monitoring device 110 may further include one or more additional sensors 150 to provide additional information that may be relevant for user monitoring. For example, the analyte monitoring device 110 may further include at least one temperature sensor (e.g., thermistor) configured to measure skin temperature, thereby enabling temperature compensation for the sensor measurements obtained by the microneedle array electrochemical sensors.
In some variations, the microneedle array 140 in the analyte monitoring device 110 may be configured to puncture skin of a user. As shown in
In contrast to traditional continuous analyte monitoring devices (e.g., CGM devices), which include sensors typically implanted between about 8 mm and about 10 mm beneath the skin surface in the subcutis or adipose layer of the skin, the analyte monitoring device 110 has a shallower microneedle insertion depth of about 0.25 mm (such that electrodes are implanted in the upper dermal region of the skin) that provides numerous benefits. These benefits include access to dermal interstitial fluid including one or more target analytes for detection, which is advantageous at least because at least some types of analyte measurements of dermal interstitial fluid have been found to closely correlate to those of blood. For example, it has been discovered that glucose measurements performed using electrochemical sensors accessing dermal interstitial fluid are advantageously highly linearly correlated with blood glucose measurements. Accordingly, glucose measurements based on dermal interstitial fluid are highly representative of blood glucose measurements.
Additionally, because of the shallower microneedle insertion depth of the analyte monitoring device 110, a reduced time delay in analyte detection is obtained compared to traditional continuous analyte monitoring devices. Such a shallower insertion depth positions the sensor surfaces in close proximity (e.g., within a few hundred micrometers or less) to the dense and well-perfused capillary bed of the reticular dermis, resulting in a negligible diffusional lag from the capillaries to the sensor surface. Diffusion time is related to diffusion distance according to t=x2/(2D) where t is the diffusion time, x is the diffusion distance, and D is the mass diffusivity of the analyte of interest. Therefore, positioning an analyte sensing element twice as far away from the source of an analyte in a capillary will result in a quadrupling of the diffusional delay time. Accordingly, conventional analyte sensors, which reside in the very poorly vascularized adipose tissue beneath the dermis, result in a significantly greater diffusion distance from the vasculature in the dermis and thus a substantial diffusional latency (e.g., typically 5-20 minutes). In contrast, the shallower microneedle insertion depth of the analyte monitoring device 110 benefits from low diffusional latency from capillaries to the sensor, thereby reducing time delay in analyte detection and providing more accurate results in real-time or near real-time. For example, in some embodiments, diffusional latency may be less than 10 minutes, less than 5 minutes, or less than 3 minutes.
Furthermore, when the microneedle array rests in the upper dermal region, the lower dermis beneath the microneedle array includes very high levels of vascularization and perfusion to support the dermal metabolism, which enables thermoregulation (via vasoconstriction and/or vasodilation) and provides a barrier function to help stabilize the sensing environment around the microneedles. Yet another advantage of the shallower insertion depth is that the upper dermal layers lack pain receptors, thus resulting in a reduced pain sensation when the microneedle array punctures the skin of the user, and providing for a more comfortable, minimally-invasive user experience.
Thus, the analyte monitoring devices and methods described herein enable improved continuous monitoring of one or more target analytes of a user. For example, as described above, the analyte monitoring device may be simple and straightforward to apply, which improves ease-of-use and user compliance. Additionally, analyte measurements of dermal interstitial fluid may provide for highly accurate analyte detection. Furthermore, compared to traditional continuous analyte monitoring devices, insertion of the microneedle array and its sensors may be less invasive and involve less pain for the user. Additional advantages of other aspects of the analyte monitoring devices and methods are further described below.
As shown in the schematic of
The microneedle array 300 may be at least partially formed from a semiconductor (e.g., silicon) substrate and include various material layers applied and shaped using various suitable microelectromechanical systems (MEMS) manufacturing techniques (e.g., deposition and etching techniques), as further described below. The microneedle array may be reflow-soldered to a circuit board, similar to a typical integrated circuit. Furthermore, in some variations the microneedle array 300 may include a three electrode setup including a working (sensing) electrode having an electrochemical sensing coating (including a biorecognition element such as an enzyme) that enables detection of a target analyte, a reference electrode, and a counter electrode. In other words, the microneedle array 300 may include at least one microneedle 310 that includes a working electrode, at least one microneedle 310 including a reference electrode, and at least one microneedle 310 including a counter electrode. Additional details of these types of electrodes are described in further detail below.
In some variations, the microneedle array 300 may include a plurality of microneedles that are insulated such that the electrode on each microneedle in the plurality of microneedles is individually addressable and electrically isolated from every other electrode on the microneedle array. The resulting individual addressability of the microneedle array 300 may enable greater control over each electrode's function, since each electrode may be separately probed. For example, the microneedle array 300 may be used to provide multiple independent measurements of a given target analyte, which improves the device's sensing reliability and accuracy. Furthermore, in some variations the electrodes of multiple microneedles may be electrically connected to produce augmented signal levels. As another example, the same microneedle array 500 may additionally or alternatively be interrogated to simultaneously measure multiple analytes to provide a more comprehensive assessment of physiological status. For example, as shown in the schematic of
In some variations of microneedles (e.g., microneedles with a working electrode), the electrode 320 may be located proximal to the insulated distal apex 316 of the microneedle. In other words, in some variations the electrode 320 does not cover the apex of the microneedle. Rather, the electrode 320 may be offset from the apex or tip of the microneedle. The electrode 320 being proximal to or offset from the insulated distal apex 316 of the microneedle advantageously provides more accurate sensor measurements. For example, this arrangement prevents concentration of the electric field at the microneedle apex 316 during manufacturing, thereby avoiding non-uniform electro-deposition of sensing chemistry on the surface of the electrode 320 that would result in faulty sensing.
As another example, placing the electrode 320 offset from the microneedle apex further improves sensing accuracy by reducing undesirable signal artefacts and/or erroneous sensor readings caused by stress upon microneedle insertion. The distal apex of the microneedle is the first region to penetrate into the skin, and thus experiences the most stress caused by the mechanical shear phenomena accompanying the tearing or cutting of the skin. If the electrode 320 were placed on the apex or tip of the microneedle, this mechanical stress may delaminate the electrochemical sensing coating on the electrode surface when the microneedle is inserted, and/or cause a small yet interfering amount of tissue to be transported onto the active sensing portion of the electrode. Thus, placing the electrode 320 sufficiently offset from the microneedle apex may improve sensing accuracy. For example, in some variations, a distal edge of the electrode 320 may be located at least about 10 μm (e.g., between about 20 μm and about 30 μm) from the distal apex or tip of the microneedle, as measured along a longitudinal axis of the microneedle.
The body portion 312 of the microneedle 310 may further include an electrically conductive pathway extending between the electrode 320 and a backside electrode or other electrical contact (e.g., arranged on a backside of the substrate of the microneedle array). The backside electrode may be soldered to a circuit board, enabling electrical communication with the electrode 320 via the conductive pathway. For example, during use, the in-vivo sensing current (inside the dermis) measured at a working electrode is interrogated by the backside electrical contact, and the electrical connection between the backside electrical contact and the working electrode is facilitated by the conductive pathway. In some variations, this conductive pathway may be facilitated by a metal via running through the interior of the microneedle body portion (e.g., shaft) between the microneedle's proximal and distal ends. Alternatively, in some variations the conductive pathway may be provided by the entire body portion being formed of a conductive material (e.g., doped silicon). In some of these variations, the complete substrate on which the microneedle array 300 is built upon may be electrically conductive, and each microneedle 310 in the microneedle array 300 may be electrically isolated from adjacent microneedles 310 as described below. For example, in some variations, each microneedle 310 in the microneedle array 300 may be electrically isolated from adjacent microneedles 310 with an insulative barrier including electrically insulative material (e.g., dielectric material such as silicon dioxide) that surrounds the conductive pathway extending between the electrode 320 and backside electrical contact. For example, body portion 312 may include an insulative material that forms a sheath around the conductive pathway, thereby preventing electrical communication between the conductive pathway and the substrate. Other example variations of structures enabling electrical isolation among microneedles are described in further detail below.
Such electrical isolation among microneedles in the microneedle array permits the sensors to be individually addressable. This individually addressability advantageously enables independent and parallelized measurement among the sensors, as well as dynamic reconfiguration of sensor assignment (e.g., to different analytes). In some variations, the electrodes in the microneedle array can be configured to provide redundant analyte measurements, which is an advantage over conventional analyte monitoring devices. For example, redundancy can improve performance by improving accuracy (e.g., averaging multiple analyte measurement values for the same analyte which reduces the effect of extreme high or low sensor signals on the determination of analyte levels) and/or improving reliability of the device by reducing the likelihood of total failure.
In some variations, as described in further detail below with respective different variations of the microneedle, the microneedle array may be formed at least in part with suitable semiconductor and/or MEMS fabrication techniques and/or mechanical cutting or dicing. Such processes may, for example, be advantageous for enabling large-scale, cost-efficient manufacturing of microneedle arrays.
In some variations, a microneedle may have a generally columnar body portion and a tapered distal portion with an electrode. For example,
The microneedle 500 may be formed at least in part by suitable MEMS fabrication techniques such as plasma etching, also called dry etching. For example, in some variations, the insulating moat 513 around the body portion 512 of the microneedle may be made by first forming a trench in a silicon substrate by deep reactive ion etching (DRIE) from the backside of the substrate, then filling that trench with a sandwich structure of SiO2/polycrystalline silicon (poly-Si)/SiO2 by low pressure chemical vapor deposition (LPCVD) or other suitable process. In other words, the insulating moat 513 may passivate the surface of the body portion 512 of the microneedle, and continue as a buried feature in the substrate 502 near the proximal portion of the microneedle. By including largely compounds of silicon, the insulating moat 513 may provide good fill and adhesion to the adjoining silicon walls (e.g., of the conductive core 540, substrate 502, etc.). The sandwich structure of the insulating moat 513 may further help provide excellent matching of coefficient of thermal expansion (CTE) with the adjacent silicon, thereby advantageously reducing faults, cracks, and/or other thermally-induced weaknesses in the insulating moat 513.
The tapered distal portion may be fashioned out by an isotropic dry etch from the frontside of the substrate, and the body portion 512 of the microneedle 500 may be formed from DRIE. The frontside metal electrode 520 may be deposited and patterned on the distal portion by specialized lithography (e.g., electron-beam evaporation) that permits metal deposition in the desired annular region for the electrode 520 without coating the distal apex 516. Furthermore, the backside electrical contact 530 of Ni/Au may be deposited by suitable MEMS manufacturing techniques (e.g., sputtering).
The microneedle 500 may have any suitable dimensions. By way of illustration, the microneedle 500 may, in some variations, have a height of between about 300 μm and about 500 μm. In some variations, the tapered distal portion 514 may have a tip angle between about 60 degrees and about 80 degrees, and an apex diameter of between about 1 μm and about 15 μm. In some variations, the surface area of the annular electrode 520 may include between about 9,000 μm2 and about 11,000 μm2, or about 10,000 μm2.
As described above, each microneedle in the microneedle array may include an electrode. In some variations, multiple distinct types of electrodes may be included among the microneedles in the microneedle array. For example, in some variations the microneedle array may function as an electrochemical cell operable in an electrolytic manner with three types of electrodes. In other words, the microneedle array may include at least one working electrode, at least one counter electrode, and at least one reference electrode. Thus, the microneedle array may include three distinct electrode types, though one or more of each electrode type may form a complete system (e.g., the system might include multiple distinct working electrodes). Furthermore, multiple distinct microneedles may be electrically joined to form an effective electrode type (e.g., a single working electrode may be formed from two or more connected microneedles with working electrode sites). Each of these electrode types may include a metallization layer and may include one or more coatings or layers over the metallization layer that help facilitate the function of that electrode.
Generally, the working electrode is the electrode at which oxidation and/or reduction reaction of interest occurs for detection of an analyte of interest. The counter electrode functions to source (provide) or sink (accumulate) the electrons, via an electrical current, that are required to sustain the electrochemical reaction at the working electrode. The reference electrode functions to provide a reference potential for the system; that is, the electrical potential at which the working electrode is biased is referenced to the reference electrode. A fixed, time-varying, or at least controlled potential relationship is established between the working and reference electrodes, and within practical limits no current is sourced from or sinked to the reference electrode. Additionally, to implement such a three-electrode system, the analyte monitoring device may include a suitable potentiostat or electrochemical analog front end to maintain a fixed potential relationship between the working electrode and reference electrode contingents within the electrochemical system (via an electronic feedback mechanism), while permitting the counter electrode to dynamically swing to potentials required to sustain the redox reaction of interest.
Working Electrode
As described above, the working electrode is the electrode at which the oxidation and/or reduction reaction of interest occurs. In some variations, sensing may be performed at the interface of the working electrode and interstitial fluid located within the body (e.g., on an outer surface of the overall microneedle). In some variations, a working electrode may include an electrode material and a biorecognition layer in which a biorecognition element (e.g., enzyme) is immobilized on the working electrode to facilitate selective analyte quantification. In some variations, the biorecognition layer may also function as an interference-blocking layer and may help prevent endogenous and/or exogenous species from directly oxidizing (or reducing) at the electrode.
A redox current detected at the working electrode may be correlated to a detected concentration of an analyte of interest. This is because assuming a steady-state, diffusion-limited system, the redox current detected at the working electrode follows the Cottrell relation below:
where n is the stoichiometric number of electrons mitigating a redox reaction, F is Faraday's constant, A is electrode surface area, D is the diffusion coefficient of the analyte of interest, C is the concentration of the analyte of interest, and t is the duration of time that the system is biased with an electrical potential. Thus, the detected current at the working electrode scales linearly with the analyte concentration.
Moreover, because the detected current is a direct function of electrode surface area A, the surface area of the electrode may be increased to enhance the sensitivity (e.g., amperes per molar of analyte) of the sensor. For example, multiple singular working electrodes may be grouped into arrays of two or more constituents to increase total effective sensing surface area. Additionally or alternatively, to obtain redundancy, multiple working electrodes may be operated as parallelized sensors to obtain a plurality of independent measures of the concentration of an analyte of interest. The working electrode can either be operated as the anode (such that an analyte is oxidized at its surface), or as the cathode (such that an analyte is reduced at its surface).
In some variations, the electrode material 612 may be coated with a highly porous electrocatalytic layer, such as a platinum black layer 613, which may augment the electrode surface area for enhanced sensitivity. Additionally or alternatively, the platinum black layer 613 may enable the electrocatalytic oxidation or reduction of the product of the biorecognition reaction facilitated by the biorecognition layer 614. However, in some variations the platinum black layer 613 may be omitted (as shown in
The biorecognition layer 614 may be arranged over the electrode material 612 (or platinum black layer 613 if it is present) and functions to immobilize and stabilize the biorecognition element which facilitates selective analyte quantification for extended time periods. In some variations, the biorecognition element may include an enzyme, such as an oxidase. As an exemplary variation for use in a glucose monitoring system, the biorecognition element may include glucose oxidase, which converts glucose, in the presence of oxygen, to an electroactive product (i.e., hydrogen peroxide) that can be detected at the electrode surface. Specifically, the redox equation associated with this exemplary variation is Glucose+OxygenHydrogen Peroxide+Gluconolactone (mediated by glucose oxidase); Hydrogen Peroxide
Water+Oxygen (mediated by applying an oxidizing potential at the working electrode).
However, in other variations the biorecognition element may additionally or alternatively comprise another suitable oxidase or oxidoreductase enzyme such as lactate oxidase, alcohol oxidase, beta-hydroxybutyrate dehydrogenase, tyrosinase, catalase, ascorbate oxidase, cholesterol oxidase, choline oxidase, pyruvate oxidase, urate oxidase, urease, and/or xanthine oxidase.
In some variations, the biorecognition element may be cross-linked with an amine-condensing carbonyl chemical species that may help stabilize the biorecognition element within the biorecognition layer 614. As further described below, in some variations, the cross-linking of the biorecognition element may result in the microneedle array being compatible with ethylene oxide (EO) sterilization, which permits exposure of the entire analyte monitoring device (including sensing elements and electronics) to the same sterilization cycle, thereby simplifying the sterilization process and lowering manufacture costs. For example, the biorecognition element may be cross-linked with glutaraldehyde, formaldehyde, glyoxal, malonaldehyde, succinaldehyde, and/or other suitable species. In some variations, the biorecognition element may be cross-linked with such an amine-condensing carbonyl chemical species to form cross-linked biorecognition element aggregates. Cross-linked biorecognition element aggregates that have at least a threshold molecular weight may then be embedded in a conducting polymer. By embedding only those aggregates that have a threshold molecular weight, any uncross-linked enzymes may be screened out and not incorporated into the biorecognition layer. Accordingly, only aggregates having a desired molecular weight may be selected for use in the conducting polymer, to help ensure that only sufficiently stabilized, cross-linked enzyme entities are included in the biorecognition layer, thereby contributing to a biorecognition layer that is overall better suited for EO sterilization without loss in sensing performance. In some variations, only cross-linked aggregates that have a molecular weight that is at least twice that of glucose oxidase may be embedded in the conducting polymer.
In some variations, the conducting polymer may be permselective to contribute to the biorecognition layer's robustness against circulating androgynous electroactive species (e.g., ascorbic acid, vitamin C, etc.), fluctuations of which may adversely affect the sensitivity of the sensor. Such a permselective conducting polymer in the biorecognition layer may further be more robust against pharmacological interferences (e.g., acetaminophen) in the interstitial fluid that may affect sensor accuracy. Conducting polymers may be made permselective by, for example, removing excess charge carriers by an oxidative electropolymerization process or by neutralizing these charge carriers with a counter-ion dopant, thereby transforming the conducting polymer into a non-conducting form. These oxidatively-polymerized conducting polymers exhibit permselectivity and are hence able to reject ions of similar charge polarity to the dopant ion (net positive or negative) or by via size exclusion due to the dense and compact form of the conducting polymers.
Furthermore, in some variations the conducting polymer may exhibit self-sealing and/or self-healing properties. For example, the conducting polymer may undergo oxidative electropolymerization, during which the conducting polymer may lose its conductivity as the thickness of the deposited conducting polymer on the electrode increases, until the lack of sufficient conductivity causes the deposition of additional conducting polymer to diminish. In the event that the conducting polymer has succumbed to minor physical damage (e.g., during use), the polymeric backbone may re-assemble to neutralize free charge and thereby lower overall surface energy of the molecular structure, which may manifest as self-sealing and/or self-healing properties.
In some variations, the working electrode may further include a diffusion-limiting layer 1615 arranged over the biorecognition layer 614. The diffusion-limiting layer 615 may function to limit the flux of the analyte of interest in order to reduce the sensitivity of the sensor to endogenous oxygen fluctuations. For example, the diffusion-limiting layer 615 may attenuate the concentration of the analyte of interest so that it becomes the limiting reactant to an aerobic enzyme. However, in some variation (e.g., if the biorecognition element is not aerobic), the diffusion-limiting layer 615 may be omitted.
The working electrode may further include, in some variations, a hydrophilic layer 616 that provides for a biocompatible interface to, for example, reduce the foreign body response. However, in some variations the hydrophilic layer 616 may be omitted (e.g., if the diffusion-limiting layer expresses hydrophilic moieties to serve this purpose), as shown in
Counter Electrode
As described above, the counter electrode is the electrode that is sourcing or sinking electrons (via an electrical current) required to sustain the electrochemical reaction at the working electrode. The number of counter electrode constituents can be augmented in the form of a counter electrode array to enhance surface area such that the current-carrying capacity of the counter electrode does not limit the redox reaction of the working electrode. It thus may be desirable to have an excess of counter electrode area versus the working electrode area to circumvent the current-carrying capacity limitation. If the working electrode is operated as an anode, the counter electrode will serve as the cathode and vice versa. Similarly, if an oxidation reaction occurs at the working electrode, a reduction reaction occurs at the counter electrode and vice versa. Unlike the working or reference electrodes, the counter electrode is permitted to dynamically swing to electrical potentials required to sustain the redox reaction of interest on the working electrode.
As shown in
In some variations, the counter electrode 620 may have few or no additional layers over the electrode material 632. However, in some variations the counter electrode 620 may benefit from increase surface area to increase the amount of current it can support. For example, the counter electrode material 632 may be textured or otherwise roughened in such a way to augment the surface area of the electrode material 632 for enhanced current sourcing or sinking ability. Additionally or alternatively, the counter electrode 620 may include a layer of platinum black 624, which may augment electrode surface as described above with respect to some variations of the working electrode. However, in some variations of the counter electrode, the layer of platinum black may be omitted (e.g., as shown in
Additionally or alternatively, in some variations as shown in
Reference Electrode
As described above, the reference electrode functions to provide a reference potential for the system; that is, the electrical potential at which the working electrode is biased is referenced to the reference electrode. A fixed or at least controlled potential relationship may be established between the working and reference electrodes, and within practical limits no current is sourced from or sinked to the reference electrode.
As shown in
The reference electrode 630 may, in some variations, further include a redox-couple layer 636, which main contain a surface-immobilized, solid-state redox couple with a stable thermodynamic potential. For example, the reference electrode may operate at a stable standard thermodynamic potential with respect to a standard hydrogen electrode (SHE). The high stability of the electrode potential may be attained by employing a redox system with constant (e.g., buffered or saturated) concentrations of each participant of the redox reaction. For example, the reference electrode may include saturated Ag/AgCl (E=+0.197V vs. SHE) or IrOx (E=+0.177 vs. SHE, pH=7.00) in the redox-couple layer 636. Other examples of redox-couple layers 636 may include a suitable conducting polymer with a dopant molecule such as that described in U.S. Patent Pub. No. 2019/0309433, which is incorporated in its entirety herein by this reference. In some variations, the reference electrode may be used as a half-cell to construct a complete electrochemical cell.
Additionally or alternatively, in some variations as shown in
Exemplary Electrode Layer Formation
Various layers of the working electrode, counter electrode, and reference electrode may be applied to the microneedle array and/or functionalized, etc. using suitable processes such as those described below.
In a pre-processing step for the microneedle array, the microneedle array may be plasma cleaned in an inert gas (e.g., RF-generated inert gas such as argon) plasma environment to render the surface of the material, including the electrode material (e.g., electrode material 612, 622, and 632 as described above), to be more hydrophilic and chemically reactive. This pre-processing functions to not only physically remove organic debris and contaminants, but also to clean and prepare the electrode surface to enhance adhesion of subsequently deposited films on its surface.
Multiple microneedles (e.g., any of the microneedle variations described herein, each of which may have a working electrode, counter electrode, or reference electrode as described above) may be arranged in a microneedle array. Considerations of how to configure the microneedles include factors such as desired insertion force for penetrating skin with the microneedle array, optimization of electrode signal levels and other performance aspects, manufacturing costs and complexity, etc.
For example, the microneedle array may include multiple microneedles that are spaced apart at a predefined pitch (distance between the center of one microneedle to the center of its nearest neighboring microneedle). In some variations, the microneedles may be spaced apart with a sufficient pitch so as to distribute force (e.g., avoid a “bed of nails” effect) that is applied to the skin of the user to cause the microneedle array to penetrate the skin. As pitch increases, force required to insert the microneedle array tends to decrease and depth of penetration tends to increase. However, it has been found that pitch only begins to affect insertion force at low values (e.g., less than about 150 μm). Accordingly, in some variations the microneedles in a microneedle array may have a pitch of at least 200 μm, at least 300 μm, at least 400 μm, at least 500 μm, at least 600 μm, at least 700 μm, or at least 750 μm. For example, the pitch may be between about 200 μm and about 800 μm, between about 300 μm and about 700 μm, or between about 400 μm and about 600 μm. In some variations, the microneedles may be arranged in a periodic grid, and the pitch may be uniform in all directions and across all regions of the microneedle array. Alternatively, the pitch may be different as measured along different axes (e.g., X, Y directions) and/or some regions of the microneedle array may include a smaller pitch while other may include a larger pitch.
Furthermore, for more consistent penetration, microneedles may be spaced equidistant from one another (e.g., same pitch in all directions). To that end, in some variations, the microneedles in a microneedle array may be arranged in a hexagonal configuration as shown in
Another consideration for determining configuration of a microneedle array is overall signal level provided by the microneedles. Generally, signal level at each microneedle is invariant of the total number of microneedle elements in an array. However, signal levels can be enhanced by electrically interconnecting multiple microneedles together in an array. For example, an array with a large number of electrically connected microneedles is expected to produce a greater signal intensity (and hence increased accuracy) than one with fewer microneedles. However, a higher number of microneedles on a die will increase die cost (given a constant pitch) and will also require greater force and/or velocity to insert into skin. In contrast, a lower number of microneedles on a die may reduce die cost and enable insertion into the skin with reduced application force and/or velocity. Furthermore, in some variations a lower number of microneedles on a die may reduce the overall footprint area of the die, which may lead to less unwanted localized edema and/or erythema. Accordingly, in some variations, a balance among these factors may be achieved with a microneedle array including 37 microneedles as shown in
Additionally, as described in further detail below, in some variations only a subset of the microneedles in a microneedle array may be active during operation of the analyte monitoring device. For example, a portion of the microneedles in a microneedle array may be inactive (e.g., no signals read from electrodes of inactive microneedles). In some variations, a portion of the microneedles in a microneedle array may be activated at a certain time during operation and remain active for the remainder of the operating lifetime of the device. Furthermore, in some variations, a portion of the microneedles in a microneedle array may additionally or alternatively be deactivated at a certain time during operation and remain inactive for the remainder of the operating lifetime of the device.
In considering characteristics of a die for a microneedle array, die size is a function of the number of microneedles in the microneedle array and the pitch of the microneedles. Manufacturing costs are also a consideration, as a smaller die size will contribute to lower cost since the number of dies that can be formed from a single wafer of a given area will increase. Furthermore, a smaller die size will also be less susceptible to brittle fracture due to the relative fragility of the substrate.
Furthermore, in some variations, microneedles at the periphery of the microneedle array (e.g., near the edge or boundary of the die, near the edge or boundary of the housing, near the edge or boundary of an adhesive layer on the housing, along the outer border of the microneedle array, etc.) may be found to have better performance (e.g., sensitivity) due to better penetration compared to microneedles in the center of the microneedle array or die. Accordingly, in some variations, working electrodes may be arranged largely or entirely on microneedles located at the periphery of the microneedle array, to obtain more accurate and/or precise analyte measurements.
Furthermore, the microneedle arrays described herein may have a high degree of configurability concerning where the working electrode(s), counter electrode(s), and reference electrode(s) are located within the microneedle array. This configurability may be facilitated by the electronics system.
In some variations, a microneedle array may include electrodes distributed in two or more groups in a symmetrical or non-symmetrical manner in the microneedle array, with each group featuring the same or differing number of electrode constituents depending on requirements for signal sensitivity and/or redundancy. For example, electrodes of the same type (e.g., working electrodes) may be distributed in a bilaterally or radially symmetrical manner in the microneedle array. For example,
As another example,
In some variations, only a portion of microneedle array may include active electrodes. For example,
As another example,
As another example,
While
Analog Front End
In some variations, the electronics system of the analyte monitoring device may include an analog front end. The analog front end may include sensor circuitry (e.g., sensor circuitry 124 as shown in
In some variations, the analog front end device may be compatible with both two and three terminal electrochemical sensors, such as to enable both DC current measurement, AC current measurement, and electrochemical impedance spectroscopy (EIS) measurement capabilities. Furthermore, the analog front end may include an internal temperature sensor and programmable voltage reference, support external temperature monitoring and an external reference source and integrate voltage monitoring of bias and supply voltages for safety and compliance.
In some variations, the analog front end may include a multi-channel potentiostat to multiplex sensor inputs and handle multiple signal channels. For example, the analog front end may include a multi-channel potentiostat such as that described in U.S. Pat. No. 9,933,387, which is incorporated herein in its entirety by this reference.
In some variations, the analog front end and peripheral electronics may be integrated into an application-specific integrated circuit (ASIC), which may help reduce cost, for example. This integrated solution may include the microcontroller described below, in some variations.
Microcontroller
In some variations, the electronics system of the analyte monitoring device may include at least one microcontroller (e.g., controller 122 as shown in
In some variations, the microcontroller may be configured to activate and/or inactivate the analyte monitoring device on one or more detected conditions. For example, the device may be configured to power on the analyte monitoring device upon insertion of the microneedle array into skin. This may, for example, enable a power-saving feature in which the battery is disconnected until the microneedle array is placed in skin, at which time the device may begin broadcasting sensor data. Such a feature may, for example, help improve the shelf life of the analyte monitoring device and/or simplify the analyte monitoring device-external device pairing process for the user.
Aspects of the current subject matter are directed to fault detection, as well as diagnostics related to the fault detection, in a microneedle array-based analyte monitoring device, such as the analyte monitoring device 110. The electrochemical sensors (e.g., electrodes of the analyte monitoring device 110) configured for measuring one or more target analytes may experience various faults during use of the analyte monitoring device 110. A fault may be a failure of one or more aspects of the analyte monitoring device 110 in which the failure affects operation of the analyte monitoring device 110. Examples of faults include degradation of the electrode membrane (e.g., cracking, delamination, and/or other damage to the membrane structure and/or surface that affects sensing), degradation of the biorecognition element (e.g., inactivation and/or denaturation), a physiologic response to implantation of the microneedle array (e.g., a foreign body response, encapsulation, protein adhesion, or collagen formation occurring in response to the insertion of the microneedles on which the electrodes are formed), improper placement or insertion of the microneedle array (e.g., the microneedles, on which the electrodes are formed, not placed at a sufficient depth for the analyte sensing), pressure attenuation (e.g., pressure applied to the analyte monitoring device 110), and external environmental influences (e.g., external impact to the electronics of the analyte monitoring device 110). The fault may affect the electrical and/or electrochemical behavior of the analyte monitoring device 110, resulting in errors and/or unreliability in measurements of the target analyte or analytes. In some instances, the fault may be temporary, such as in the case of pressure attenuations. In other instances, the fault may permanently affect operation of the analyte monitoring device 110.
Some faults may be detectable by monitoring the current draw. For example, a value of the sensing current at the working electrode of the analyte monitoring device 110 may indicate and/or correlate to some faults. In these instances, if the sensing current exhibits extreme, erratic, and/or unexpected behaviors or patterns, the fault may be determinable based on characteristics of the exhibited behaviors or patterns of the sensing current. The extreme, erratic, and/or unexpected behaviors or patterns of the sensing current may be characterized by rapid rates of change that are non-physiologically capable or possible. High noise may also contribute to the behaviors or patterns of the sensing current.
Other faults, however, may not impact the sensing current while still impacting the electrical and/or electrochemical behavior of the analyte monitoring device 110. An alternative or additional variable is thus needed for insight to and verification of changes to the electrical and/or electrochemical behavior of the analyte monitoring device 110. Voltage at the counter electrode is an example of a variable that provides such insight and verification. Thus, by monitoring the voltage at the counter electrode, a fault may be detected.
While various types of faults, such as those described above, may occur, faults may generally be characterized by if the analyte monitoring device 110 can recover from the fault (e.g., the fault is temporary) or if the analyte monitoring device 110 is damaged and operation should cease (e.g., the fault is permanent). By monitoring the counter electrode voltage, as well as, in some variations, how the counter electrode voltage corresponds with or is correlated to the sensing current, such a characterization may be made and a response to the fault may be determined. The response to the fault may be in the form of a mode of operation in which to operate the analyte monitoring device. For example, if the fault is temporary, the mode of operation may include blanking and/or disregarding any sensing data during the fault. In this situation, sensing data is inaccurate and thus not reported to the user or used for operational purposes. If the fault is permanent, the mode of operation may be to stop operation of the analyte monitoring device. In some variations, this may include ceasing application of a bias potential between the working electrode and the reference electrode.
In some variations, the counter electrode voltage is monitored to identify one or more characteristics that may serve as an indication of a fault. The characteristics indicative of a fault may include a rate of change of the counter electrode voltage and/or a lower compliance limit of the counter electrode voltage. The characteristics may be explained by considering the relationship between the counter electrode potential and the current at the working electrode. That is, as further described herein, the counter electrode voltage dynamically swings or adjusts to electrical potentials required to sustain the redox reaction at the working electrode. The counter electrode voltage may thus be considered as the voltage that is required to support the level of current at the working electrode (e.g., the sensing current). As the sensing current fluctuates or changes, the counter electrode voltage fluctuates or changes in a corresponding or reciprocal manner. If the sensing current experiences a rapid rate of change, the counter electrode voltage responds with a rapid rate of change. The correspondence, or correlation, between the sensing current and the counter electrode voltage may be defined as equal but opposite in rate of change (or near equal but opposite (e.g., up to about a 5% difference between the rates of change)). If the sensing current changes at a specified rate, the counter electrode voltage changes at the specified rate in the opposite direction. The rate of change of the counter electrode voltage then serves as an indicator of the rate of change of the sensing current. A sensing current that exhibits a rapid rate of change is non-physiologically capable or possible. Thus, by monitoring the counter electrode voltage, a determination may be made as to the physiological viability of the sensing current. As a rapid rate of change is not physiologically possible, such a change serves as an indication that something is wrong with the device. In some variations, a rapid rate of change of the counter electrode voltage may be defined as about 0.10 volts/minute. In some variations, a rapid rate of change of the counter electrode voltage may be defined as between about 0.05 volts/minute and about 0.15 volts/minute. For example, in some variations, a rapid rate of change of the counter electrode voltage may be defined as about 0.05 volts/minute, about 0.06 volts/minute, about 0.07 volts/minute, about 0.08 volts/minute, about 0.09 volts/minute, about 0.10 volts/minute, about 0.11 volts/minute, about 0.12 volts/minute, about 0.13 volts/minute, about 0.14 volts/minute, or about 0.15 volts/minute. A rapid rate of change of the sensing current may be associated with a rate of change of the analyte being measured. In the example of glucose, a rapid rate of change may be about 4 mg/dL/min. In some variations, a rapid rate of change of glucose may be between about 3.5 mg/dL/min and about 6 mg/dL/min.
The lower compliance limit of the counter electrode voltage may be defined as the lowest level to which the counter electrode voltage may swing. The counter electrode voltage may also have an upper compliance limit, the highest level to which the counter electrode may swing. If the counter electrode voltage swings to the lower compliance limit, this may serve as an indication that the sensing current reached a high magnitude current that is not physiologically capable, indicating occurrent of a fault.
Thus, the counter electrode voltage experiencing a rate of change that meets or exceeds a threshold rate of change and/or meets a threshold compliance limit serve as indications that there is a fault within the analyte monitoring device 110. In some variations, upon identifying that the rate of change of the counter electrode voltage meets or exceeds a threshold rate of change and/or that the counter electrode voltage meets a threshold compliance limit, characteristics or parameters of the counter electrode voltage may be compared to characteristics or parameters of the sensing current to determine if the fault is temporary or permanent. The comparison may include determination of the correspondence, or correlation, between the counter electrode voltage and the sensing current.
In some variations, the counter electrode voltage corresponding with the sensing current such that the counter electrode voltage is changing in an equal rate of change as that of the sensing current, is representative of a pressure-induced signal attenuation. Such a pressure-induced signal attenuation may be caused by external pressure being applied to the analyte monitoring device 110 and may be characterized as a temporary fault. When the external pressure is removed, the analyte monitoring device 110 operates as intended.
In some variations, changes in the counter electrode voltage corresponding with changes in the sensing current, such that the correspondence is maintained, coupled with the counter electrode voltage meeting a lower compliance limit is representative of changes in the physiologic environment surrounding the sensor and/or changes in the sensor surface. In other variations, the counter electrode voltage meeting the lower compliance limit, regardless of the sensing current, is representative of a change in the physiologic environment and/or changes in the sensor surface. In this scenario, the counter electrode voltage does not need to be correlated with the sensing current. Changes in the physiologic environment surrounding the sensor and changes in the sensor surface may be examples of permanent faults.
In some variations, changes in the counter electrode voltage deviating from the changes in the sensing current, such that the counter electrode voltage and the sensing current are changing in different ways, coupled with the rapid rate of change of the counter electrode voltage, may be representative of an external impact to the electronics of the analyte monitoring device. An external impact may be an example of a permanent fault.
When the correlation between the counter electrode voltage and the sensing current is determined, the analyte monitoring device 110 (e.g., the controller) responds by applying a mode of operation consistent with the fault. For example, based on the identified characteristic of the counter electrode voltage and the correspondence of the counter electrode voltage and the sensing current, a mode of operation is applied to the microneedle array-based analyte monitoring device.
In some variations, the mode of operation includes disregarding the sensing current if the changes in the counter electrode voltage correspond with the changes in the sensing current and if the rate of change of the counter electrode voltage exceeds a threshold rate of change. As described herein, this may be representative of pressure-induced signal attenuation. When the pressure-induced signal attenuation is removed from the counter electrode voltage and the sensing current (e.g., the rate of change of the counter electrode voltage does not exceed the threshold rate of change), the sensing current is no longer disregarded as the fault has been remedied.
In some variations, the mode of operation includes discontinuing application of a potential between the working electrode and the reference electrode if the changes in the counter electrode voltage correspond with the changes in the sensing current and if the lower compliance limit of the counter electrode voltage meets a threshold compliance limit. The threshold compliance limit being reached is an indication of a permanent fault, and the bias potential is removed to stop operation.
In some variations, the mode of operation includes discontinuing application of a potential between the working electrode and the reference electrode if the changes in the counter electrode voltage deviate from the changes in the sensing current and if the rate of change of the counter electrode voltage exceeds a threshold rate of change. This is an indication of a permanent fault, and the bias potential is removed to stop operation.
As further described herein, the reference electrode functions to provide a reference potential for the three-electrode electrochemical system implemented by the analyte monitoring device 110. The electrical potential at which the working electrode is biased is referenced to the reference electrode. A fixed, time-varying, or at least controlled potential relationship is established between the working and reference electrodes, and within practical limits no current is sourced from or sinked to the reference electrode. To implement such a three-electrode electrochemical system, the analyte monitoring device 110 includes a potentiostat or an electrochemical analog front end (e.g., an analog front end) to maintain a fixed potential relationship between the working electrode and the reference electrode within the three-electrode electrochemical system, while permitting the counter electrode to dynamically swing to potentials required to sustain the redox reaction of interest. Biasing the electrochemical system with the potentiostat or the analog front end to establish the electrical potential relationship between the working electrode and the reference electrode drives the redox reaction at the working electrode and causes the counter electrode to sink an electrical current in an oxidative process or source an electrical current in a reductive process to sustain the redox reaction at the working electrode. The magnitude of the electrical current is proportional to the magnitude of the redox reaction occurring at the working electrode and to the impedance or resistance between the working electrode and the counter electrode. Biasing the electrochemical system results in formation of a voltage at the counter electrode, the value of which is also proportional to the magnitude of the redox reaction at the working electrode and to the impedance or resistance between the working electrode and the counter electrode.
The voltage at the counter electrode adjusts to the electrical potential to balance the redox reaction occurring at the working electrode when maintained at the electrical potential versus the reference electrode. Upon occurrence of a fault, in which one or more aspects of the analyte monitoring device 110 affects operation of the analyte monitoring device 110, the voltage at the counter electrode is modulated and reflective of the accumulated impedance between the working electrode and the counter electrode. By monitoring the voltage at the counter electrode, an indication of the impedance between the working electrode and the counter electrode may be determined. The three-electrode electrochemical system of the analyte monitoring device 110 can be modeled as an electrical network or system, including electrical components to correlate the voltage at the counter electrode with the impedance or resistance between the working electrode and the counter electrode, which can be correlated with one or more conditions, including fault types. By associating or characterizing the impedance with certain conditions including faults of the three-electrode electrochemical system, voltage values can be correlated with one or more faults.
The Randles equivalent circuit 1100 of the electrochemical cell 1010 of the analyte monitoring device 110 is a simplification of the redox reaction occurring within the electrochemical cell 1010. By modeling the electrochemical cell 1010 with the Randles equivalent circuit 1100, contributions from the solution resistance Rs, the charge-transfer resistance Rct, and the double-layer capacitance Cdl may be identified. A frequency response analysis, including amplitude and phase components, may be used to understand the impedance behavior of the electrochemical cell 1010 at DC (ω0) and at AC (ω
∞) frequency perturbations. The voltage at the counter electrode 1120, in the DC case, provides an assessment of the overall resistive components of the system (e.g., Rs+Rct) as Cdl is assumed to have infinite impedance as ω
0. In the other extreme, as ω
∞, Cdl approaches negligible impedance and Rct is bypassed. This allows the quantification of Rs alone, which may be realized with an impulse or unit step function applied to the counter electrode 1120.
In the DC case (ω0), the voltage at the counter electrode 1120 is expected to swing to more extreme values, to the compliance voltage of the potentiostat, when additional current must be sourced or sinked to maintain the fixed potential relationship between the working electrode and the reference electrode. This is manifested via the counter electrode voltage migrating away from the voltage established at the working electrode 1110. In extreme cases, the voltage at the counter electrode 1120 approaches the compliance voltage, or the maximal voltage afforded by the circuit driving the counter electrode 1120. The manifestation of this mode of operation in the Randles equivalent circuit is a charge transfer resistance Rct that tends toward the value of the solution resistance Rs. In the DC case, this is an indication that one or more of the following faults is occurring: a short circuit generated between the working electrode and the counter electrode, a failure of the reference electrode's ability to maintain a stable thermodynamic potential, a compromise to a diffusion-limiting membrane, and a steady increase of the porosity of the sensing layer contained within analyte-selective sensor.
The counter electrode voltage approaches the voltage value in which the working electrode 1110 is maintained in scenarios in which the current requirements to sustain the fixed potential relationship between the working electrode and the reference electrode tend toward negligible values (e.g., inconsequential values of current flow through the system, i0). The manifestation of this mode of operation in the Randles equivalent circuit is a charge transfer resistance Rct that tends toward infinity. In the DC case, this is an indication that one or more of the following faults is occurring: improper sensor insertion, improper access to a viable anatomic compartment, partial or complete occlusion of the sensor (e.g., due to biofouling/protein adsorption/collagen formation/encapsulation) such that analyte diffusion is attenuated, and a failure of the reference electrode's ability to maintain a stable thermodynamic potential.
Measurement of the voltage at the counter electrode may be achieved by a potentiostat, an electrochemical analog front end, or a converter, such as a voltage-sensitive or current-sensitive analog-to-digital converter (ADC).
In some instances, and as shown in a measurement circuit 1200 in
In some instances, a voltage arising at one or more working electrodes is measured and used to supplement and/or complement the fault identification. The working electrode voltage may be compared against a counter electrode voltage to assess and/or determine the fault. An analog-to-digital converter may be in electrical communication with the working electrode. In some implementations, a galvanostat is incorporated to establish a desired electrical current relationship between the working electrode and the counter electrode.
Scenarios where the voltage at a counter electrode approaches that of the voltage at the working electrode is indicative of an impedance or resistance value of an analyte sensor decaying to low levels, by merit of Ohm's Law (v=Zi, where Z is the accumulated impedance of the analyte sensor). This is an indication that any one or more of the following faults is occurring: a short circuit generated between the working electrode and the counter electrode, a failure of the reference electrode's ability to maintain a stable thermodynamic potential, a compromise to a diffusion-limiting membrane, or a steady increase of the porosity of the sensing layer contained within analyte-selective sensor. The counter electrode voltage approaches the working electrode voltage in situations in which the counter electrode voltage is swinging in a positive direction to support the level of current at the working electrode (e.g., the sensing current).
If the difference between the voltage at the counter electrode and the voltage at the working electrode increases, this is indicative of an impedance or resistance value of an analyte sensor increasing to very large values. This is an indication that any one or more of the following faults is occurring: improper sensor insertion, partial or complete occlusion of the sensor (e.g., due to biofouling/protein adsorption/collagen formation/encapsulation) such that analyte diffusion is attenuated, or a failure of the reference electrode's ability to maintain a stable thermodynamic potential. The difference between the counter electrode voltage and the working electrode voltage increasing occurs when the counter electrode voltage swings in a negative direction to support the sensing current.
Thus, in some instances, a voltage is measured at the working electrode and the counter electrode to identify the fault. The voltage value of the counter electrode adjusts dynamically to support the prescribed current requirements of the analyte sensor, as shown in
0 intersection enables the calculation of a double-layer capacitance Cdl.
Faults are indicated at points 1421, 1422, 1423, 1424, and 1425 in the counter electrode voltage and correspond, respectively, to points 1411, 1412, 1413, 1414, and 1415 in the sensing current. The faults at points 1421, 1422, 1423, 1424, and 1425 are representative of pressure-induced signal attenuations and are identified by deviation in the correspondence between the counter electrode voltage and the sensing current. As shown in the plots 1410 and 1420, at the faults, the counter electrode voltage corresponds to the sensing current with an equal or near equal rate of change. For example, the rates of change may differ between one another by up to 5% or in some instances up to 10%.
Faults are indicated at points 1521, 1522, 1523, and 1524 in the counter electrode voltage and correspond, respectively, to points 1511, 1512, 1513, and 1514 in the sensing current. The faults at points 1521, 1522, 1523, and 1524 are representative of pressure-induced signal attenuations and are identified by deviation in the correspondence between the counter electrode voltage and the sensing current. As shown in the plots 1510 and 1520, at the faults, the counter electrode voltage corresponds to the sensing current with an equal or near equal rate of change. For example, the rates of change may differ between one another by up to 5% or in some instances up to 10%.
The counter electrode voltage reaching a lower compliance limit at point 1621 is an indication of a fault. The point 1621 may correspond to a preceding current spike at point 1611 in the sensor current, but in some instances, it may not be a clear correlation between the counter electrode voltage and the sensing current. The fault at 1621, based on the lower compliance limit being reached, is representative of changes in the physiologic environment surrounding the sensor or changes in the sensor surface.
The digitized voltage signals are transmitted to a controller 1822 coupled to each converter. In some instances, the controller 122 shown in and described with reference to
In some variations, more than one working electrode is incorporated and used for detecting an analyte. For example, in the microneedle array configurations 900H, 900I, and/or 900J, shown in
With more than one working electrode, each additional working electrode generates a respective sensing current. In some variations, a correlation between the counter electrode voltage and each working electrode sensing current may be determined. As each working electrode is positioned on a separate and discrete microneedle in the microneedle array, faults that arise may not be consistent between the working electrodes. For example, electrode membrane degradation and biorecognition element degradation may vary across the plurality of working electrodes. Additionally, with respect to improper placement or insertion, in some instances the working electrodes may experience different insertion depths such that while one or more working electrodes are sufficiently inserted, others may not be. Pressure attenuations may also, in some instances, affect the working electrodes differently. Therefore, based on the differences that can occur across the microneedle array, it may be useful to separately monitor and analyze the counter electrode voltage against each working electrode sensing current. The separate monitoring and analysis may serve to provide an indication of a fault at one or more working electrodes. In some variations, when one fault is identified, a corresponding mode of operation is applied.
If more than one fault is identified and the faults are different, the mode of operation to discontinue application of a potential between the working electrode and the reference electrode takes a priority over the mode of operation to blank and/or disregard sensing data. In some variations, if a fault is detected at one working electrode but one or more additional working electrodes are operating according to normal operation (e.g., no fault detected), the potential applied at the working electrode exhibiting a fault may be discontinued while allowing operation to continue with the remaining working electrodes. In some variations, a minimum number of operational working electrodes may be defined such that operation of the analyte monitoring device continues if the number of operational working electrodes meets or exceeds the minimum number.
In some variations, a combined sensing current is based on the working electrode sensing currents being combined. For example, the sensing current from each of the working electrodes may be averaged to form a combined sensing current. The combined sensing current may be used with the counter electrode voltage, as described herein, to determine faults and modes of operation of the analyte monitoring device.
Additional details related to the Randles equivalent model are provided. The impedance Z of the Randles equivalent model is given by the relation:
Z=Rs+Rct∥Cdl [1]
Expanding this relation to represent the impedance as a function of radian frequency ω:
At the DC case (zero frequency), the impedance is given by:
{tilde over (Z)}(ω→0)=Rs+Rct [3]
At the AC case (high frequency extreme), the impedance is given by:
{tilde over (Z)}(ω→∞)=Rs [4]
Recasting equation 2:
The real and imaginary components of the impedance given in equation 5 may be easily identified as:
Given a substitution:
ξ=1+ω2Rct2Cdl2 [8]
The amplitude response of the system is given by:
The phase response is accordingly computed:
The current supported by the electrochemical reaction iCELL may be computed by applying Kirchoff s Voltage Law to the Randles cell:
The counter electrode voltage, VCE, may be computed by reformulating the above relation:
The current may be a positive or negative quantity depending on the configuration of the potentiostat and whether the electrochemical reaction is undergoing oxidation or reduction. In the provided model and current worked equations, it is assumed that the current flows from the counter electrode (held at highest potential) through the electrochemical cell and into the working electrode, which is held at a lower potential (e.g., ground-referenced); this model assumes a reduction reaction (e.g., current flows into the working electrode and thus acts as an electron source). It is also possible for the counter electrode to be held at a lower potential than the working electrode (in oxidation), causing the current to flow from the working electrode into the counter electrode. In this case, the working electrode acts as an electron sink.
For the DC case:
VCE=VWE+iCELL[Rs+Rct] [13]
For a given Rs and Rct, VCE will track iCELL. For a finite charge transfer resistance Rct:
This is the compliance voltage limit of the potentiostat. In this scenario, there is no ohmic connection between the counter electrode and working electrode. Likewise:
This represents the ideal operating condition for an electrochemical system. This is achieved by operating in a medium of sufficient electrolytic/ionic strength (e.g., buffer solution or a physiological fluid of a wearer). Likewise, for a finite solution resistance Rs:
In other words, the counter electrode voltage will approach the working electrode voltage as the current through the electrochemical cell, iCELL, approaches zero due to an infinite charge-transfer resistance. The practical manifestation of this is a complete passivation of the working electrode surface such that no current can flow; an ideal double-layer capacitor is thus formed. As for the case when the said charge transfer resistance approaches zero:
The current through the electrochemical cell becomes invariant of the charge transfer process (e.g., as in an electrolysis reaction). Instead, the counter electrode will track the current flowing through the electrochemical cell (assuming the solution resistance/electrolytic content remains constant throughout the electrolysis).
In the AC case, as the frequency tends towards extreme values:
The current through the electrochemical cell becomes invariant of the charge transfer process (e.g., as in an electrolysis reaction). Similarly, in the DC case, as the frequency tends towards zero:
This is the same as equation 13.
The foregoing description, for purposes of explanation, used specific nomenclature to provide a thorough understanding of the invention. However, it will be apparent to one skilled in the art that specific details are not required in order to practice the invention. Thus, the foregoing descriptions of specific embodiments of the invention are presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed; obviously, many modifications and variations are possible in view of the above teachings. The embodiments were chosen and described in order to explain the principles of the invention and its practical applications, they thereby enable others skilled in the art to utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is intended that the following claims and their equivalents define the scope of the invention.
This application claims priority to U.S. Provisional Patent No. 63/186,086, filed May 8, 2021, the contents of which are hereby incorporated in their entirety by this reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4305401 | Reissmueller et al. | Dec 1981 | A |
| 4323996 | Ganter | Apr 1982 | A |
| 4407295 | Steuer et al. | Oct 1983 | A |
| 4450842 | Zick et al. | May 1984 | A |
| 4908117 | Kinlen et al. | Mar 1990 | A |
| 4969468 | Byers et al. | Nov 1990 | A |
| 5035711 | Aoki et al. | Jul 1991 | A |
| 5131390 | Sakaguchi et al. | Jul 1992 | A |
| 5279543 | Glikfeld et al. | Jan 1994 | A |
| 5286364 | Yacynych et al. | Feb 1994 | A |
| 5540828 | Yacynych | Jul 1996 | A |
| 5730714 | Guy et al. | Mar 1998 | A |
| 5766132 | Yasukawa et al. | Jun 1998 | A |
| 5832410 | Lin et al. | Nov 1998 | A |
| 5869078 | Baudino | Feb 1999 | A |
| 5953306 | Yi | Sep 1999 | A |
| 6036055 | Mogadam et al. | Mar 2000 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6132449 | Lum et al. | Oct 2000 | A |
| 6132499 | Wong et al. | Oct 2000 | A |
| 6132755 | Eicher et al. | Oct 2000 | A |
| 6139718 | Kurnik et al. | Oct 2000 | A |
| 6269053 | Kawata et al. | Jul 2001 | B1 |
| 6284126 | Kurnik et al. | Sep 2001 | B1 |
| 6364890 | Lum et al. | Apr 2002 | B1 |
| 6413396 | Yang et al. | Jul 2002 | B1 |
| 6465091 | Ou-yang | Oct 2002 | B1 |
| 6471903 | Sherman et al. | Oct 2002 | B2 |
| 6527762 | Santini, Jr. et al. | Mar 2003 | B1 |
| 6551849 | Kenney | Apr 2003 | B1 |
| 6587705 | Kim et al. | Jul 2003 | B1 |
| 6599408 | Chan et al. | Jul 2003 | B1 |
| 6603987 | Whitson | Aug 2003 | B2 |
| 6611707 | Prausnitz et al. | Aug 2003 | B1 |
| 6793789 | Choi et al. | Sep 2004 | B2 |
| 6801041 | Karinka et al. | Oct 2004 | B2 |
| 6814845 | Wilson et al. | Nov 2004 | B2 |
| 6862466 | Ackerman | Mar 2005 | B2 |
| 6908453 | Fleming et al. | Jun 2005 | B2 |
| 7081195 | Simpson et al. | Jul 2006 | B2 |
| 7097776 | Govinda Raju | Aug 2006 | B2 |
| 7132054 | Kravitz et al. | Nov 2006 | B1 |
| 7262068 | Roy et al. | Aug 2007 | B2 |
| 7343188 | Sohrab | Mar 2008 | B2 |
| 7344499 | Prausnitz et al. | Mar 2008 | B1 |
| 7366556 | Brister et al. | Apr 2008 | B2 |
| 7415299 | Zimmermann et al. | Aug 2008 | B2 |
| 7429333 | Chiou et al. | Sep 2008 | B2 |
| 7456112 | Lee | Nov 2008 | B2 |
| 7471972 | Rhodes et al. | Dec 2008 | B2 |
| 7473244 | Frazier et al. | Jan 2009 | B2 |
| 7493232 | Surina | Feb 2009 | B1 |
| 7534330 | Yu et al. | May 2009 | B2 |
| 7583990 | Goode, Jr. | Sep 2009 | B2 |
| 7599726 | Goode, Jr. | Oct 2009 | B2 |
| 7613491 | Boock | Nov 2009 | B2 |
| 7645263 | Angel et al. | Jan 2010 | B2 |
| 7715893 | Kamath et al. | May 2010 | B2 |
| 7768408 | Reggiardo et al. | Aug 2010 | B2 |
| 7778680 | Goode, Jr. | Aug 2010 | B2 |
| 7797028 | Goode, Jr. | Sep 2010 | B2 |
| 7811231 | Jin et al. | Oct 2010 | B2 |
| 7837654 | Shumate et al. | Nov 2010 | B2 |
| 7885697 | Brister et al. | Feb 2011 | B2 |
| 7905833 | Brister et al. | Mar 2011 | B2 |
| 7917186 | Kamath et al. | Mar 2011 | B2 |
| 7949382 | Jina | May 2011 | B2 |
| 7959569 | Goode et al. | Jun 2011 | B2 |
| 8005526 | Martin et al. | Aug 2011 | B2 |
| 8010174 | Goode, Jr. | Aug 2011 | B2 |
| 8022292 | Arianpour et al. | Sep 2011 | B2 |
| 8064977 | Boock et al. | Nov 2011 | B2 |
| 8088321 | Ferguson et al. | Jan 2012 | B2 |
| 8094009 | Allen et al. | Jan 2012 | B2 |
| 8108023 | Mir et al. | Jan 2012 | B2 |
| 8110079 | Gooding et al. | Feb 2012 | B2 |
| 8125331 | Allen et al. | Feb 2012 | B2 |
| 8130095 | Allen et al. | Mar 2012 | B2 |
| 8160665 | Mischler et al. | Apr 2012 | B2 |
| 8160671 | Kamath et al. | Apr 2012 | B2 |
| 8160834 | Liang et al. | Apr 2012 | B2 |
| 8162901 | Gonnelli et al. | Apr 2012 | B2 |
| RE43399 | Simpson et al. | May 2012 | E |
| 8216138 | McGarraugh | Jul 2012 | B1 |
| 8236368 | Jung et al. | Aug 2012 | B2 |
| 8249684 | Kamath et al. | Aug 2012 | B2 |
| 8257324 | Prausnitz et al. | Sep 2012 | B2 |
| 8280475 | Brister et al. | Oct 2012 | B2 |
| 8280476 | Jina | Oct 2012 | B2 |
| 8284046 | Allen et al. | Oct 2012 | B2 |
| 8287453 | Li et al. | Oct 2012 | B2 |
| 8308960 | Kälvesten et al. | Nov 2012 | B2 |
| 8346335 | Harper et al. | Jan 2013 | B2 |
| 8376945 | Hayter et al. | Feb 2013 | B2 |
| 8386004 | Kamath et al. | Feb 2013 | B2 |
| 8423114 | Simpson et al. | Apr 2013 | B2 |
| 8428678 | Kamath et al. | Apr 2013 | B2 |
| 8452369 | Huys et al. | May 2013 | B2 |
| 8463350 | Kamath et al. | Jun 2013 | B2 |
| 8483793 | Simpson et al. | Jul 2013 | B2 |
| 8506529 | Yang | Aug 2013 | B1 |
| 8548553 | Kamath et al. | Oct 2013 | B2 |
| 8565848 | Brister et al. | Oct 2013 | B2 |
| 8574165 | Marsh | Nov 2013 | B2 |
| 8617069 | Bernstein et al. | Dec 2013 | B2 |
| RE44695 | Simpson et al. | Jan 2014 | E |
| 8626257 | Li et al. | Jan 2014 | B2 |
| 8637351 | Kälvesten et al. | Jan 2014 | B2 |
| 8660628 | Wang et al. | Feb 2014 | B2 |
| 8708966 | Allen et al. | Apr 2014 | B2 |
| 8798799 | Deo et al. | Aug 2014 | B2 |
| 8815070 | Wang et al. | Aug 2014 | B2 |
| 8870763 | Yang et al. | Oct 2014 | B2 |
| 8882665 | Yang et al. | Nov 2014 | B2 |
| 9008743 | Hayter et al. | Apr 2015 | B2 |
| 9008745 | Pushpala et al. | Apr 2015 | B2 |
| 9055901 | Brister et al. | Jun 2015 | B2 |
| 9125625 | Wang et al. | Sep 2015 | B2 |
| 9182368 | Pushpala et al. | Nov 2015 | B2 |
| 9234872 | Homyk et al. | Jan 2016 | B2 |
| 9248273 | Guvanasen et al. | Feb 2016 | B2 |
| 9332934 | Hayter et al. | May 2016 | B2 |
| 9336423 | Goodnow et al. | May 2016 | B2 |
| 9357951 | Simpson et al. | Jun 2016 | B2 |
| 9386954 | Saini et al. | Jul 2016 | B2 |
| 9387000 | Corrie et al. | Jul 2016 | B2 |
| 9414778 | Mao et al. | Aug 2016 | B2 |
| 9420965 | Brauker et al. | Aug 2016 | B2 |
| 9532741 | Brauker et al. | Jan 2017 | B2 |
| 9551698 | Huys et al. | Jan 2017 | B2 |
| 9662056 | Budiman et al. | May 2017 | B2 |
| 9737247 | Wang et al. | Aug 2017 | B2 |
| 9743870 | Wang et al. | Aug 2017 | B2 |
| 9743871 | Simpson et al. | Aug 2017 | B2 |
| 9757061 | Shults et al. | Sep 2017 | B2 |
| 9770211 | Hayter et al. | Sep 2017 | B2 |
| 9804114 | Rhodes et al. | Oct 2017 | B2 |
| 9933387 | McCanna et al. | Apr 2018 | B1 |
| 9958409 | Gerber et al. | May 2018 | B2 |
| 10022076 | Hoss et al. | Jul 2018 | B2 |
| 10039480 | Brauker et al. | Aug 2018 | B2 |
| 10046114 | Biederman et al. | Aug 2018 | B1 |
| 10052055 | Li et al. | Aug 2018 | B2 |
| 10092207 | Windmiller | Oct 2018 | B1 |
| 10136846 | Wang et al. | Nov 2018 | B2 |
| 10173042 | Pushpala et al. | Jan 2019 | B2 |
| 10182748 | Catt et al. | Jan 2019 | B2 |
| 10188333 | Kamath et al. | Jan 2019 | B2 |
| 10228341 | Katsuki et al. | Mar 2019 | B2 |
| 10299712 | Brister et al. | May 2019 | B2 |
| 10327678 | Gottlieb et al. | Jun 2019 | B2 |
| 10492708 | Windmiller | Dec 2019 | B1 |
| D875254 | Cooke et al. | Feb 2020 | S |
| 10549080 | Pushpala et al. | Feb 2020 | B2 |
| 10610103 | Brister et al. | Apr 2020 | B2 |
| 10709332 | Brister et al. | Jul 2020 | B2 |
| 10743800 | Larvenz et al. | Aug 2020 | B2 |
| 10820860 | Pushpala et al. | Nov 2020 | B2 |
| 10881334 | Facchinetti et al. | Jan 2021 | B2 |
| 10932700 | Simpson et al. | Mar 2021 | B2 |
| 10983083 | Harding et al. | Apr 2021 | B2 |
| 11020026 | Boock et al. | Jun 2021 | B2 |
| 11035872 | Boutelle et al. | Jun 2021 | B2 |
| 11045142 | Windmiller et al. | Jun 2021 | B1 |
| 11051724 | Pace et al. | Jul 2021 | B2 |
| 11123532 | Pushpala et al. | Sep 2021 | B2 |
| 11179068 | Pace et al. | Nov 2021 | B2 |
| 11197985 | Pushpala et al. | Dec 2021 | B2 |
| 11272866 | Pushpala et al. | Mar 2022 | B2 |
| 11272885 | Pushpala et al. | Mar 2022 | B2 |
| 11291390 | Pushpala et al. | Apr 2022 | B2 |
| 11331022 | Halac et al. | May 2022 | B2 |
| 11359300 | Beer et al. | Jun 2022 | B1 |
| 11406818 | Windmiller | Aug 2022 | B2 |
| 11478194 | Windmiller et al. | Oct 2022 | B2 |
| 11596332 | Shults et al. | Mar 2023 | B2 |
| 11654270 | Mansfield, III et al. | May 2023 | B2 |
| D988160 | Morelock | Jun 2023 | S |
| 11672965 | Mansfield, III et al. | Jun 2023 | B2 |
| D996999 | Morelock | Aug 2023 | S |
| 20020004640 | Conn et al. | Jan 2002 | A1 |
| 20020020688 | Sherman et al. | Feb 2002 | A1 |
| 20020055704 | Scott et al. | May 2002 | A1 |
| 20020072784 | Norman, Jr. et al. | Jun 2002 | A1 |
| 20020105080 | Speakman | Aug 2002 | A1 |
| 20020187556 | Shartle et al. | Dec 2002 | A1 |
| 20030088166 | Say et al. | May 2003 | A1 |
| 20030095582 | Ackley | May 2003 | A1 |
| 20030100040 | Bonnecaze et al. | May 2003 | A1 |
| 20030104119 | Wilson et al. | Jun 2003 | A1 |
| 20030135158 | Gonnelli | Jul 2003 | A1 |
| 20030208167 | Prausnitz et al. | Nov 2003 | A1 |
| 20030225360 | Eppstein et al. | Dec 2003 | A1 |
| 20030235817 | Bartkowiak et al. | Dec 2003 | A1 |
| 20040065158 | Schrepfer et al. | Apr 2004 | A1 |
| 20040082875 | Donoghue et al. | Apr 2004 | A1 |
| 20040220625 | Silvestri et al. | Nov 2004 | A1 |
| 20050036020 | Li et al. | Feb 2005 | A1 |
| 20050137536 | Gonnelli | Jun 2005 | A1 |
| 20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
| 20050267440 | Herman et al. | Dec 2005 | A1 |
| 20050272989 | Shah et al. | Dec 2005 | A1 |
| 20060015061 | Kuo et al. | Jan 2006 | A1 |
| 20060016700 | Brister et al. | Jan 2006 | A1 |
| 20060173259 | Flaherty et al. | Aug 2006 | A1 |
| 20060264716 | Zander | Nov 2006 | A1 |
| 20060281121 | Unger et al. | Dec 2006 | A1 |
| 20070078445 | Malloy | Apr 2007 | A1 |
| 20070169533 | Shah et al. | Jul 2007 | A1 |
| 20070170054 | Wilsey | Jul 2007 | A2 |
| 20070213044 | Steingart et al. | Sep 2007 | A1 |
| 20070282246 | Henley | Dec 2007 | A1 |
| 20080009800 | Nickel | Jan 2008 | A1 |
| 20080009801 | Nickel | Jan 2008 | A1 |
| 20080027369 | Carter et al. | Jan 2008 | A1 |
| 20080033269 | Zhang | Feb 2008 | A1 |
| 20080097280 | Martin et al. | Apr 2008 | A1 |
| 20080097352 | Beck et al. | Apr 2008 | A1 |
| 20080119707 | Stafford | May 2008 | A1 |
| 20080154107 | Jina | Jun 2008 | A1 |
| 20080156661 | Cooper et al. | Jul 2008 | A1 |
| 20080213461 | Gill et al. | Sep 2008 | A1 |
| 20080221408 | Hoarau et al. | Sep 2008 | A1 |
| 20080234562 | Jina | Sep 2008 | A1 |
| 20080255434 | Hayter et al. | Oct 2008 | A1 |
| 20080275327 | Faarbaek et al. | Nov 2008 | A1 |
| 20090057148 | Wieder | Mar 2009 | A1 |
| 20090066348 | Shin et al. | Mar 2009 | A1 |
| 20090069651 | Zimmermann et al. | Mar 2009 | A1 |
| 20090069697 | Frazier et al. | Mar 2009 | A1 |
| 20090084678 | Joshi et al. | Apr 2009 | A1 |
| 20090088652 | Tremblay | Apr 2009 | A1 |
| 20090090623 | Chuang et al. | Apr 2009 | A1 |
| 20090099427 | Jina et al. | Apr 2009 | A1 |
| 20090101498 | Papadimitrakopoulos et al. | Apr 2009 | A1 |
| 20090131778 | Jina et al. | May 2009 | A1 |
| 20090143761 | Cantor et al. | Jun 2009 | A1 |
| 20090152598 | Baek et al. | Jun 2009 | A1 |
| 20090191616 | Lu et al. | Jul 2009 | A1 |
| 20090198118 | Hayter et al. | Aug 2009 | A1 |
| 20090218239 | Gooding et al. | Sep 2009 | A1 |
| 20090259118 | Feldman et al. | Oct 2009 | A1 |
| 20090294306 | Feldman et al. | Dec 2009 | A1 |
| 20100006451 | Gordon et al. | Jan 2010 | A1 |
| 20100021637 | Revol et al. | Jan 2010 | A1 |
| 20100025238 | Gottlieb et al. | Feb 2010 | A1 |
| 20100030045 | Gottlieb et al. | Feb 2010 | A1 |
| 20100049021 | Jina et al. | Feb 2010 | A1 |
| 20100052892 | Allen et al. | Mar 2010 | A1 |
| 20100052897 | Allen et al. | Mar 2010 | A1 |
| 20100052898 | Allen et al. | Mar 2010 | A1 |
| 20100052915 | Allen et al. | Mar 2010 | A1 |
| 20100056873 | Allen et al. | Mar 2010 | A1 |
| 20100137779 | Seitz | Jun 2010 | A1 |
| 20100200538 | Petisce et al. | Aug 2010 | A1 |
| 20100279377 | Shah et al. | Nov 2010 | A1 |
| 20100286803 | Tillotson et al. | Nov 2010 | A1 |
| 20110027127 | Simpson et al. | Feb 2011 | A1 |
| 20110077490 | Simpson et al. | Mar 2011 | A1 |
| 20110105871 | Zimmermann et al. | May 2011 | A1 |
| 20110140703 | Chiao et al. | Jun 2011 | A1 |
| 20110224515 | Mir et al. | Sep 2011 | A1 |
| 20110230736 | Tepper et al. | Sep 2011 | A1 |
| 20110237925 | Yue et al. | Sep 2011 | A1 |
| 20110247934 | Wang et al. | Oct 2011 | A1 |
| 20110275918 | Yamashita et al. | Nov 2011 | A1 |
| 20110306853 | Black et al. | Dec 2011 | A1 |
| 20110319787 | Lamoise et al. | Dec 2011 | A1 |
| 20120018302 | Shiraki et al. | Jan 2012 | A1 |
| 20120037515 | Solanki | Feb 2012 | A1 |
| 20120067734 | Wang et al. | Mar 2012 | A1 |
| 20120078071 | Bohm et al. | Mar 2012 | A1 |
| 20120123232 | Najarian et al. | May 2012 | A1 |
| 20120172692 | Tamada et al. | Jul 2012 | A1 |
| 20120209244 | Gray | Aug 2012 | A1 |
| 20120277629 | Bernstein et al. | Nov 2012 | A1 |
| 20120323097 | Chowdhury | Dec 2012 | A9 |
| 20130053660 | Shieh | Feb 2013 | A1 |
| 20130065257 | Wang et al. | Mar 2013 | A1 |
| 20130135158 | Faraone et al. | May 2013 | A1 |
| 20130144131 | Wang et al. | Jun 2013 | A1 |
| 20130158376 | Hayter et al. | Jun 2013 | A1 |
| 20130225956 | Huang et al. | Aug 2013 | A1 |
| 20130281808 | Shieh | Oct 2013 | A1 |
| 20130338746 | Guvanasen et al. | Dec 2013 | A1 |
| 20130345597 | Hagino et al. | Dec 2013 | A1 |
| 20140135679 | Mann et al. | May 2014 | A1 |
| 20140259652 | Pushpala et al. | Sep 2014 | A1 |
| 20140275897 | Pushpala et al. | Sep 2014 | A1 |
| 20140275899 | Gottlieb et al. | Sep 2014 | A1 |
| 20140275907 | Feldman et al. | Sep 2014 | A1 |
| 20140303471 | Rajaraman et al. | Oct 2014 | A1 |
| 20140336487 | Wang et al. | Nov 2014 | A1 |
| 20140378804 | Kalvesten et al. | Dec 2014 | A1 |
| 20150073238 | Matsumoto et al. | Mar 2015 | A1 |
| 20150126834 | Wang et al. | May 2015 | A1 |
| 20150208970 | Huang | Jul 2015 | A1 |
| 20150243851 | Lee et al. | Aug 2015 | A1 |
| 20150276758 | Addisu | Oct 2015 | A1 |
| 20150313527 | Renlund | Nov 2015 | A1 |
| 20160029937 | Sia et al. | Feb 2016 | A1 |
| 20160058342 | Maiz-Aguinaga et al. | Mar 2016 | A1 |
| 20160095541 | Wang et al. | Apr 2016 | A1 |
| 20160095547 | Wang et al. | Apr 2016 | A1 |
| 20160139069 | Wang | May 2016 | A1 |
| 20160157764 | Di Palma et al. | Jun 2016 | A1 |
| 20160158514 | Stoeber et al. | Jun 2016 | A1 |
| 20160166184 | Teng et al. | Jun 2016 | A1 |
| 20160258945 | Malima et al. | Sep 2016 | A1 |
| 20160270704 | Deturk | Sep 2016 | A1 |
| 20160296149 | Polsky et al. | Oct 2016 | A1 |
| 20160302687 | Lee et al. | Oct 2016 | A1 |
| 20160370377 | Ahmad | Dec 2016 | A1 |
| 20170003766 | Budiman | Jan 2017 | A1 |
| 20170007813 | Negi et al. | Jan 2017 | A1 |
| 20170035331 | Parajape et al. | Feb 2017 | A1 |
| 20170086713 | Pushpala et al. | Mar 2017 | A1 |
| 20170127989 | Feldman et al. | May 2017 | A1 |
| 20170128009 | Pushpala et al. | May 2017 | A1 |
| 20170164881 | Fujita | Jun 2017 | A1 |
| 20170251959 | Feldman et al. | Sep 2017 | A1 |
| 20170251960 | Crouther et al. | Sep 2017 | A1 |
| 20170347925 | Wang et al. | Dec 2017 | A1 |
| 20180116572 | Simpson et al. | May 2018 | A1 |
| 20180140235 | Pushpala et al. | May 2018 | A1 |
| 20180279929 | Huang et al. | Oct 2018 | A1 |
| 20180317820 | Pace et al. | Nov 2018 | A1 |
| 20180338712 | Cass et al. | Nov 2018 | A1 |
| 20190008425 | Srinivasan et al. | Jan 2019 | A1 |
| 20190022365 | Chowdhury et al. | Jan 2019 | A1 |
| 20190029577 | Koelker et al. | Jan 2019 | A1 |
| 20190090811 | Reitz et al. | Mar 2019 | A1 |
| 20190091455 | Reitz et al. | Mar 2019 | A1 |
| 20190094169 | Shah et al. | Mar 2019 | A1 |
| 20190110724 | Kamath et al. | Apr 2019 | A1 |
| 20190125223 | Wang et al. | May 2019 | A1 |
| 20190167167 | Mitchell et al. | Jun 2019 | A1 |
| 20190209095 | Kamath et al. | Jul 2019 | A1 |
| 20190223795 | Patolsky et al. | Jul 2019 | A1 |
| 20190224712 | Petisce et al. | Jul 2019 | A1 |
| 20190241926 | Mckinlay et al. | Aug 2019 | A1 |
| 20190261907 | Brister et al. | Aug 2019 | A1 |
| 20190274599 | Polsky et al. | Sep 2019 | A1 |
| 20190274600 | Pesantez et al. | Sep 2019 | A1 |
| 20190298210 | Bennet et al. | Oct 2019 | A1 |
| 20190307379 | Boock et al. | Oct 2019 | A1 |
| 20190309433 | Sattayasamitsathit et al. | Oct 2019 | A1 |
| 20190310219 | Boock | Oct 2019 | A1 |
| 20190357827 | Li et al. | Nov 2019 | A1 |
| 20200029876 | Brister et al. | Jan 2020 | A1 |
| 20200037938 | Rong et al. | Feb 2020 | A1 |
| 20200085341 | Windmiller | Mar 2020 | A1 |
| 20200101286 | Windmiller et al. | Apr 2020 | A1 |
| 20200121902 | Pushpala et al. | Apr 2020 | A1 |
| 20200178853 | Pushpala et al. | Jun 2020 | A1 |
| 20200187778 | Brister et al. | Jun 2020 | A1 |
| 20200214566 | Allen et al. | Jul 2020 | A1 |
| 20200254240 | Windmiller et al. | Aug 2020 | A1 |
| 20200297997 | Windmiller et al. | Sep 2020 | A1 |
| 20200305771 | Feldman et al. | Oct 2020 | A1 |
| 20200359949 | Brauker et al. | Nov 2020 | A1 |
| 20200405234 | Pushpala et al. | Dec 2020 | A1 |
| 20210045663 | Simpson et al. | Feb 2021 | A1 |
| 20210045665 | Simpson et al. | Feb 2021 | A1 |
| 20210045666 | Simpson et al. | Feb 2021 | A1 |
| 20210100452 | Brister et al. | Apr 2021 | A1 |
| 20210100504 | Pushpala et al. | Apr 2021 | A1 |
| 20210100505 | Pushpala et al. | Apr 2021 | A1 |
| 20210183508 | Parker et al. | Jun 2021 | A1 |
| 20210187286 | Windmiller et al. | Jun 2021 | A1 |
| 20210190719 | LaTour et al. | Jun 2021 | A1 |
| 20210345916 | Boock et al. | Nov 2021 | A1 |
| 20210353229 | Pierart et al. | Nov 2021 | A1 |
| 20210379370 | Windmiller et al. | Dec 2021 | A1 |
| 20210386338 | Zhang et al. | Dec 2021 | A1 |
| 20210393201 | Morelock et al. | Dec 2021 | A1 |
| 20220031244 | Windmiller et al. | Feb 2022 | A1 |
| 20220047190 | Taylor et al. | Feb 2022 | A1 |
| 20220054813 | Pushpala et al. | Feb 2022 | A1 |
| 20220054814 | Pushpala et al. | Feb 2022 | A1 |
| 20220104773 | Lee et al. | Apr 2022 | A1 |
| 20220151516 | Wang et al. | May 2022 | A1 |
| 20220151518 | Pushpala et al. | May 2022 | A1 |
| 20220151519 | Pushpala et al. | May 2022 | A1 |
| 20220151558 | Pushpala et al. | May 2022 | A1 |
| 20220175278 | Campbell et al. | Jun 2022 | A1 |
| 20220175279 | Pushpala et al. | Jun 2022 | A1 |
| 20220175282 | Hoss et al. | Jun 2022 | A1 |
| 20220214300 | Wang et al. | Jul 2022 | A1 |
| 20220225901 | Chapman et al. | Jul 2022 | A1 |
| 20220233107 | Pushpala et al. | Jul 2022 | A1 |
| 20220249189 | Choi et al. | Aug 2022 | A1 |
| 20220298291 | Shin et al. | Sep 2022 | A1 |
| 20220322975 | Baker et al. | Oct 2022 | A1 |
| 20220322977 | Simpson et al. | Oct 2022 | A1 |
| 20220370011 | Windmiller et al. | Nov 2022 | A1 |
| 20230074798 | Tangney et al. | Mar 2023 | A1 |
| 20230094419 | Mansfield, III et al. | Mar 2023 | A1 |
| 20230099617 | Mansfield, III et al. | Mar 2023 | A1 |
| 20230137258 | Windmiller | May 2023 | A1 |
| 20230190147 | Campbell et al. | Jun 2023 | A1 |
| 20230256220 | Mansfield et al. | Aug 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 101068591 | Nov 2007 | CN |
| 112617822 | Apr 2021 | CN |
| 1006868 | Jun 2004 | EP |
| 1 372 602 | Apr 2007 | EP |
| 1792565 | Oct 2008 | EP |
| 1 187 653 | Mar 2010 | EP |
| 2 898 821 | Dec 2017 | EP |
| 3 381 370 | Oct 2018 | EP |
| H0222552 | Jan 1990 | JP |
| H-02-031741 | Feb 1990 | JP |
| H-07-275227 | Oct 1995 | JP |
| 2003-038464 | Feb 2003 | JP |
| 2003-038465 | Feb 2003 | JP |
| 2005-087613 | Apr 2005 | JP |
| 2006-510467 | Apr 2005 | JP |
| 2005-525141 | Aug 2005 | JP |
| 2005-322591 | Nov 2005 | JP |
| 2008-512162 | Apr 2008 | JP |
| 2008-540013 | Nov 2008 | JP |
| 2017108763 | Jun 2017 | JP |
| 2019205852 | Dec 2019 | JP |
| 2020170011 | Oct 2020 | JP |
| 2022501100 | Jan 2022 | JP |
| 10-2016-0108111 | Sep 2016 | KR |
| WO-0074763 | Dec 2000 | WO |
| WO-0074763 | Dec 2000 | WO |
| WO-2006060106 | Jun 2006 | WO |
| WO-2006093422 | Sep 2006 | WO |
| WO-2006116242 | Nov 2006 | WO |
| WO-2006116242 | Nov 2006 | WO |
| WO-2007040938 | Apr 2007 | WO |
| WO-2009034313 | Mar 2009 | WO |
| WO-2009034313 | Mar 2009 | WO |
| WO-2009064164 | May 2009 | WO |
| WO-2009064164 | May 2009 | WO |
| WO-2009124095 | Oct 2009 | WO |
| WO-2010014959 | Feb 2010 | WO |
| WO-2010014959 | Feb 2010 | WO |
| WO-2010022252 | Feb 2010 | WO |
| WO-2010022252 | Feb 2010 | WO |
| WO-2010045247 | Apr 2010 | WO |
| WO-2010059276 | May 2010 | WO |
| WO-2010120364 | Oct 2010 | WO |
| WO-2010120364 | Oct 2010 | WO |
| WO-2011056095 | May 2011 | WO |
| WO-2012020332 | Feb 2012 | WO |
| WO-2012020332 | Feb 2012 | WO |
| WO-2012142625 | Oct 2012 | WO |
| WO-2012142625 | Oct 2012 | WO |
| WO-2013058879 | Apr 2013 | WO |
| WO-2013058879 | Apr 2013 | WO |
| WO-2014120114 | Aug 2014 | WO |
| WO-2015073459 | May 2015 | WO |
| WO-2016189301 | Dec 2016 | WO |
| WO-2017129980 | Aug 2017 | WO |
| WO-2017189707 | Nov 2017 | WO |
| WO-2018017196 | Jan 2018 | WO |
| WO-2018071265 | Apr 2018 | WO |
| WO-2018164886 | Sep 2018 | WO |
| WO-2018170363 | Sep 2018 | WO |
| WO-2019156934 | Aug 2019 | WO |
| WO-2019222615 | Nov 2019 | WO |
| WO-2019239258 | Dec 2019 | WO |
| WO-2020023804 | Jan 2020 | WO |
| WO-2020117918 | Jun 2020 | WO |
| WO-2021015389 | Jan 2021 | WO |
| WO-2021025260 | Feb 2021 | WO |
| WO-2021086690 | May 2021 | WO |
| WO-2021118124 | Jun 2021 | WO |
| WO-2021118431 | Jun 2021 | WO |
| WO-2022026764 | Feb 2022 | WO |
| WO-2022066985 | Mar 2022 | WO |
| WO-2022066992 | Mar 2022 | WO |
| WO-2022090741 | May 2022 | WO |
| WO-2022136785 | Jun 2022 | WO |
| WO-2023055755 | Apr 2023 | WO |
| WO-2023064877 | Apr 2023 | WO |
| WO-2023133468 | Jul 2023 | WO |
| Entry |
|---|
| Abbot press release (2020). “New late-breaking data show use of abbott's Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not,” 3 pages. |
| American Diabetes Association® Press Release (2020). “American Diabetes Association® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans,” 4 pages. |
| Bantle, J.P. et al. (1997). “Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid,” J. Lab. Clin. Med. 130:436-441. |
| Beckles, G.L. et al. (2016). “Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014,” MMWR 65:1265-1269. |
| Cao, J. et al. (2017). “Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system,” Pract. Lab. Med. 9:24-27. |
| Castle, J.R. et al. (2012). “The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes,” Diabetes Care 35:706-710. |
| Chang, H. et al. (2017). “A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic analysis,” Adv. Mater. 29:1702243. |
| Dexcom (2020). Analyst Day Presentation, 27 total pages. |
| Dexcom (2020). Analyst Day Presentation, 19 total pages. |
| Diabetes Care (2021). “7. Diabetes Technology: Standards of Medical Care in Diabetes—2021,” Diabetes Care 44(Supplement 1):S85-S99. |
| Donnelly, R.F. et al. (2007). “Microstructured Devices for Transdermal Drug Delivery and Minimally-Invasive Patient Monitoring,” Recent Patents on Drug Delivery & Formulation 1:195-200. |
| Extended European Search Report dated May 8, 2015, for EP Application No. 12 842 020.5, filed on Aug. 31, 2012, 7 pages. |
| Extended European Search Report dated Oct. 27, 2022, for EP Application No. 21 850 331.6, filed on Jul. 29, 2021, 8 pages. |
| Fang, M. et al. (2021). “Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018,” N. Engl. Med. 384:2219-2228. |
| Final Office Action dated Aug. 19, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages. |
| Final Office Action dated Nov. 28, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 34 pages. |
| Final Office Action dated May 18, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 23 pages. |
| Final Office Action dated Dec. 7, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages. |
| Final Office Action dated May 21, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 11 pages. |
| Final Office Action dated Jun. 9, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 24 pages. |
| Final Office Action dated Sep. 23, 2021, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 17 pages. |
| Final Office Action dated May 9, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 17 pages. |
| Final Office Action dated Aug. 15, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages. |
| Final Office Action dated Oct. 27, 2022, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 21 pages. |
| French, D.P. et al. (2008). “Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial,” Diav. Med. 25:1218-1228. |
| Gittard, S.D. et al. (2009). “Fabrication of Polymer Microneedles Using a Two-Photon Polymerization and Micromolding Process,” J. Diabetes Sci. Technol. 3:304-311. |
| Grady, M. et al. (2017). “Examining the Impact of a Novel Blood Glucose Monitor With Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level,” JMIR Diabetes 2:e24. |
| Grady, M. et al. (2018). “Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients with Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study),” J. Diab. Sci. Tech. 12:1211-1219. |
| Groenendaal, W. et al. (2008). “Modeling Glucose and Water Dynamics in Human Skin,” Diab. Tech. Therap. 10:283-293. |
| International Search Report dated Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 7 pages. |
| International Search Report dated Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 2 pages. |
| International Search Report dated Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 2 pages. |
| International Search Report dated Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages. |
| International Search Report dated Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 2 pages. |
| International Search Report dated Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 4 pages. |
| Jeon, G. et al. (2011). “Electrically Actuatable Smart Nanoporous Membrane for Pulsatile Drug Release,” Nano Lett. 11:1284-1288. |
| Jina, A et al. (2014). “Design, development, and evaluation of a novel microneedle array-based continuous glucose monitor,” J. Diabetes Sci. Technol. 8:483-487. |
| Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes,” N. Engl. Med. 359:1464-1476. |
| Karter, A.J. et al. (2021). “Association of Real-time Continuous Glucose Monitoring with Glycemic Control and Acute Metabolic Events Among Patients with Insulin-Treated Diabetes,” JAMA 325:2273-2284. |
| Lhernould, M.S. et al. (2015). “Review of Patents for Microneedle Application Devices Allowing Fluid Injections Through the Skin,” Recent Patents on Drug Delivery & Formulation 9:146-157. |
| Malitesta et al. (1990). “Glucose fast-response amperometric sensor based on glucose oxidase immobilized in an electropolymerized poly(o-phenylenediamine) film,” Anal. Chem. 62:2735-2740. |
| Martens, T. et al. (2021). “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin a Randomized Clinical Trial,” JAMA 325:2262-2272. |
| McClatchey, P.M. et al. (2019). “Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays,” Diabetes 68:1892-1901. |
| Miller, P.R. et al. (2011). “Integrated carbon fiber electrodes within hollow polymer microneedles for transdermal electrochemical sensing,” BioMicrofluidics 5(1):013415. |
| Mohan, A.M. (2017). “Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays,” Biosensors and Bioelectronics 91:574-579. |
| Neerken, S. et al. (2004). “Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography,” J. Biomed. Optics 9:274-281. |
| Non-Final Office Action dated Mar. 10, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 15 pages. |
| Non-Final Office Action dated Mar. 30, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 31 pages. |
| Non-Final Office Action dated Mar. 9, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages. |
| Non-Final Office Action dated Apr. 6, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 32 pages. |
| Non-Final Office Action dated Nov. 1, 2017, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 19 pages. |
| Non-Final Office Action dated Jan. 19, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 11 pages. |
| Non-Final Office Action dated Apr. 13, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages. |
| Non-Final Office Action dated Sep. 3, 2020, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 19 pages. |
| Non-Final Office Action dated Sep. 16, 2020, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 15 pages. |
| Non-Final Office Action dated Oct. 16, 2020, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 13 pages. |
| Non-Final Office Action dated Nov. 4, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 20 pages. |
| Non-Final Office Action dated Nov. 26, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages. |
| Non-Final Office Action dated Nov. 29, 2021, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 14 pages. |
| Non-Final Office Action dated Apr. 8, 2022, for U.S. Appl. No. 17/650,056, filed Feb. 4, 2022, 14 pages. |
| Non-Final Office Action dated May 13, 2022, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 20 pages. |
| Non-Final Office Action dated Dec. 21, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 12 pages. |
| Notice of Allowance dated Jul. 6, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 12 pages. |
| Notice of Allowance dated Jul. 12, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 14 pages. |
| Notice of Allowance dated Feb. 13, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 8 pages. |
| Notice of Allowance dated Aug. 24, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 7 pages. |
| Notice of Allowance dated May 25, 2021, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 11 pages. |
| Notice of Allowance dated Sep. 12, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 8 pages. |
| Polonsky, W.H. et al. (2011). “A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?” Curr. Med. Res. & Opinion 27:31-37. |
| Rigla, M. et al. (2018). “Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy,” Diabetes Technology & Therapeutics 20:296-302. |
| Sachdeva, V. et al. (2011). “Microneedles and their applications,” Recent Patents on Drug Delivery & Formulation 5:95-132. |
| Sheikh, Z. et al. (2015). “Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials,” Materials 8:5671-5701. |
| Shi, T. et al. (2016). “Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes,” J. Diab. Res. vol. 2016, 9 pages. |
| Singh, T.R.R. et al. (2010). “Microporation techniques for enhanced delivery of therapeutic agents,” Recent Patents on Drug Delivery & Formulation 4:1-17. |
| Texas Instruments (Sep. 2007). Data sheet for a LMP2234 quad micropower, 1.6V, precision, operational amplifier with CMOS input, Sep. 2007, revised Mar. 2013, 31 total pages. |
| Windmiller, J.R. (2012). “Molecular scale biocomputing: An enzyme logic approach,” University of California, San Diego, A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Electrical Engineering (Photonics), 78 total pages. |
| Windmiller, J.R. et al. (2011). “Bicomponent microneedle array biosensor for minimally-invasive glutamate monitoring,” Electroanalysis 23:2302-2309. |
| Windmiller, J.R. et al. (2011). “Microneedle array-based carbon paste amperometric sensors and biosensors,” Analyst 136:1846-1851. |
| Written Opinion of the International Searching Authority dated Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 10 pages. |
| Written Opinion of the International Searching Authority dated Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 4 pages. |
| Written Opinion of the International Searching Authority dated Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 5 pages. |
| Written Opinion of the International Searching Authority dated Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages. |
| Written Opinion of the International Searching Authority dated Aug. 29, 2022, for PCT Appiication No. PCT/US2022/028196, filed on May 6, 2022, 5 pages. |
| Written Opinion of the International Searching Authority dated Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 15 pages. |
| Yoon, Y. et al. (2013). “Fabrication of a Microneedle/CNT Hierarchical Micro/Nano Surface Electrochemical Sensor and Its In-Vitro Glucose Sensing Characterization,” Sensors 13:16672-16681. |
| Al Hayek et al., “Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study” Cureus Oct. 27, 2020; 12(10):e11195. doi: 10.7759/cureus.11195. |
| Allen et al., “Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial” Diabetes Res Clin Pract. Jun. 2008; 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006. |
| Barrett et al., “Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years—United States, Mar. 1, 2020-Jun. 28, 2021” MMWR Morb Mortal Wkly Rep. Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2. |
| Centers for Disease Control, “National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States” (2020) 32 pages. |
| Dunkin et al., “Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers” Plast Reconstr Surg. May 2007; 119(6):1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0. |
| Ehrhardt et al, “The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus” Journal of Diabetes Science and Technology May 2011; 5(3):668-675. |
| Ehrhardt et al, “Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring” Journal of Diabetes Science and Technology Mar. 2019; 13(2):271-275. |
| Ehrhardt et al., “Continuous Glucose Monitoring As a Behavior Modification Tool” Clin Diabetes. Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037. |
| Extended European Search Report dated Mar. 30, 2023, for European Application No. EP20881425.1, 8 pages. |
| Fonda et al., “The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes” Journal of Diabetes Science and Technology (2016) 10(4):898-904. |
| Han et al., “The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?” Journal of Diabetes Science and Technology (2020) 14(3):595-600. |
| Han et al., “The YSI 2300 Analyzer Replacement Meeting Report” Journal of Diabetes Science and Technology (2020) 14(3):679-686. |
| Non-Final Office Action dated Jan. 27, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 15 pages. |
| Non-Final Office Action dated Feb. 16, 2023 for U.S. Appl. No. 17/738,990, 9 pages. |
| Non-Final Office Action dated Mar. 9, 2023 for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 24 pages. |
| Non-Final Office Action dated May 2, 2023 for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 18 pages. |
| Sharifi et al., “Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring” Journal of Diabetes Science and Technology (2016) 10(3):669-678. |
| Swedish Search Report dated Feb. 3, 2023 for SE Application No. 2350067-1, 7 pages. |
| Turner et al., “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)” The Lancet Sep. 1998; 352(9131):837-853. |
| Vigersky et al., “Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes” Diabetes Care Jan. 2012; 35:32-38. |
| Wolicki et al., “Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration” Centers for Disease Control and Prevention (2021) 17 pages. |
| World Health Organization, “Diabetes”, Sep. 16, 2022, 5 pages. |
| Young et al., “Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial” JAMA Intern Med. Jul. 2017; 177(7):920-929. |
| Brown, “Design of Electronics for Wearable Electrochemical Sensors” University of California, San Diego, Master's Thesis (2019) 48 pages. |
| Final Office Action dated Aug. 29, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 17 pages. |
| Non-Final Office Action dated May 24, 2023, for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 19 pages. |
| Non-Final Office Action dated Jun. 2, 2023, for U.S. Appl. No. 17/367,274, filed Jul. 2, 2021, 27 pages. |
| Non-Final Office Action dated Jun. 20, 2023, for U.S. Appl. No. 17/073,331, filed Oct. 17, 2020, 10 pages. |
| Notice of Allowance dated Jun. 12, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 14 pages. |
| Supplementary European Search Report dated Oct. 9, 2023, for EP Application No. 22808101.4, 4 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20220370011 A1 | Nov 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63186086 | May 2021 | US |
